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EIS INHIBITORS 
RELATED APPLICATIONS 
This application claims priority from U.S. Provisional 
Application Ser. Nos. 62/595,947 filed Dec. 7, 2017, and 
62/431,744 filed Dec. 8, 2016, the entire disclosures of 
which are incorporated herein by this reference. 
GOVERNMENT INTEREST 
This invention was made with govermnent support under 
National Institutes of Health (NIH) Grant AI090048. The 
govermnent has certain rights in the invention. 
TECHNICAL FIELD 
The presently-disclosed subject matter relates to compo-
sitions useful as inhibitors of acetyltransferase Eis, a media-
tor ofkanamycin resistance in Mycobacterium tuberculosis, 
and their methods of use. In particular, the compositions are 
sulfonamide-based and sulfonyl isothiazole-based small 
molecules. 
INTRODUCTION 
A major cause of tuberculosis (TB) resistance to the 
aminoglycoside kanamycin (KAN) is the Mycobacterium 
tuberculosis (Mtb) acetyltransferase Eis. Eis is a super-
acetyltransferase from M. tuberculosis that inactivates all 
clinically used aminoglycosides. Upregulation of Eis is a 
frequent cause of clinical resistance to the aminoglycoside 
kanamycin (KAN) in TB. Upregulation of this enzyme is 
responsible for inactivation of KAN through acetylation of 
its amino groups. 
Tuberculosis (TB) is an infectious disease caused by 
Mycobacterium tuberculosis (Mtb ), and a major global 
health threat. In 2013, approximately 9.0 million people 
developed TB, and nearly 1.5 million died from the disease. 
Due to the spread of multidrug-resistant TB (MDR TB), 
defined as TB with resistance to at least isoniazid and 
rifampin (-10% of new TB cases in 2013) and extensively 
drug-resistant TB (XDR TB), defined as MDR TB with 
added resistance to at least a fluoroquinolone and an inject-
able drug (i.e., kanamycin (KAN), capreomycin, or amika-
cin), the need for novel strategies to combat drug resistant 
TB is urgent. 
The aminoglycosides (AGs) kanamycin A (KAN) and 
amikacin (AMK) are used to treat MDR- and XDR-TB, but 
resistance to these agents occurs as well. Among mecha-
nisms of clinically important transmissible drug resistance is 
the recently identified inactivation of an MDR-TB therapeu-
tic, the aminoglycoside kanamycin, through its acetylation 
2 
Furthermore, Eis homologues from Mycobacterium smeg-
matis, Mycobacterium abscessus, Anabaena variabilis, 
Bacillus anthracis, Gordonia bronchialis, Kocuria rhizo-
phila (9), and Tsukamurella paurometabola are also func-
5 tional AACs, which exhibit differences in regiospecificity 
and can be inhibited by chlorhexidine, a non-clinically 
relevant Eis Mtb inhibitor. In addition to AG substrate 
versatility, E~ enzymes display some acyl-CoAco-substrate 
promiscuity and can acetylate non-AG molecules containing 
10 lysine residues, such as capreomycin and the JNK-specific 
dual-specificity protein phosphatase 16 (DUSP16)/mitogen-
activated protein kinase phosphatase-7 (MKP-7) pair. These 
observations underscore the uniqueness and versatility of 
Eis AG modifying activity and its high capacity for inacti-
15 vation of diverse AG drugs. 
The development of AGs that cannot be modified by Eis 
or a novel therapy that would involve an Eis inhibitor used 
in combination with KAN are two possible approaches to 
resolve the need in the field of drug resistant tuberculosis. 
20 The former route is complicated by the ability of Eis to 
accept structurally diverse AGs as substrates, whereas the 
latter route is potentially more suitable. The latter approach 
to combat drug resistance arising as a result of drug-
modifying enzymes, then, is to use a combination therapy 
that includes an antibiotic along with an inhibitor of its 25 
associated resistance enzyme. In Mtb, including MDR TB, 
the combination of the ~-lactamase inhibitor clavulanate and 
the ~-lactam meropenem was demonstrated to overcome 
resistance to ~-lactam antibiotics. With this strategy in mind, 
efforts have also been made towards identifying inhibitors of 
30 aminoglycoside acetyltransferases (AACs) present in non-
mycobacteria, with limited pre-clinical progress, but these 
are not applicable for the mechanistically and structurally 
distinct Mtb Eis acetyltransferase. For example, aminogly-
coside-acetyl coenzyme A bi-substrate inhibitors were found 
35 to potently inhibit AAC(6') enzymes in vitro, but were not 
effective in cell-based assays. Numerous cationic peptides 
that inhibit AAC(6') enzymes in vitro were identified, but 
these also displayed no antibacterial effects against resistant 
bacterial strains due to membrane permeability issues. 
40 Finally, the natural product aranorosin was found to be an 
inhibitor of the bifunctional AAC(6')-Ie/APH(2")-Ia 
enzyme, and its combination with the aminogly_c~si_de 
arbekacin was shown to stop the growth of a methic1llm-
resistant Staphylococcus aureus strain. 
We previously reported that some Eis inhibitors displayed 
45 AG-competitive and mixed modes of action, establishing a 
proof of principle for inhibition of Eis in vitro. 
A two-drug combination therapy where one drug targets 
an offending cell and the other targets a resistance mecha-
nism to the first drug is a time-tested, yet underexploited 
50 approach to combat or prevent drug resistance in an infec-
tious disease. Furthermore, there remains a need for 
approaches to combat drug resistant TB. by an up regulated acety ltransferase, the Eis ( enhanced intra-
cellular survival) enzyme. We previously demonstrated that 
the Mtb Eis protein (Eis_Mtb) is an acetyltransferase 
capable of multiacetylating a variety of AGs, including the 55 
TB therapeutics KAN and AMK, via a random sequential 
mechanism, thereby abolishing the antibiotic activity of 
these drugs. The ability of acetylating an AG molecule at 
multiple amine positions due to its unique structure distin-
guishes Eis from other AG acetyltransferases (AA Cs), 
which are known to be exquisitely regiospecific. A crystal 60 
structure of Eis_Mtb in complex with coenzyme A and 
tobramycin demonstrated how tobramycin could interact 
with the Eis active site in two binding modes for the 
observed diacetylation of the 6'- and 3"-amines of this AG. 
SUMMARY 
The presently-disclosed subject matter meets some or all 
of the above-identified needs, as will become evident to 
those of ordinary skill in the art after a study of information 
provided in this document. 
This S=ary describes several embodiments of the 
presently-disclosed subject matter, and in many cases lists 
variations and permutations of these embodiments. This 
Summary is merely exemplary of the numerous and varied 
embodiments. Mention of one or more representative 
features of a given embodiment is likewise exemplary. Such 
an embodiment can typically exist with or without the 
feature(s) mentioned; likewise, those features can be applied 
Multiacetylation by Eis has a defined pattern for each AG: 65 
the number of acetylations and the positions of the amino 
groups that get acetylated depend on the structure of the AG. 
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to other embodiments of the presently-disclosed subject 
matter, whether listed in this Summary or not. To avoid 
excessive repetition, this Summary does not list or suggest 
all possible combinations of such features. 
The presently-disclosed subject matter includes com-
pounds, compositions, and methods involving inhibition of 
Eis. In some embodiments, the compound has a scaffolds 
selected from the following: 
CC~~-0 
~ ~~ 
R 
and 
4 
5 
The presently-disclosed subject matter also includes a 
10 pharmaceutical composition comprising a compound as 
described herein, and a suitable pharmaceutical carrier. 
15 
In some embodiments, the composition includes a com-
pound as described herein and an aminoglycoside. In some 
embodiments, the aminoglycoside is kanamycin (KAN). 
The presently-disclosed subject matter also includes a 
method of inhibiting Eis, which involves administering an 
effective amount of a compound or composition as described 
herein. In some embodiments, the method further involves 
administering an aminoglycoside. In some embodiments, 
20 the aminoglycoside is kanamycin (KAN). 
The presently-disclosed subject matter also includes a 
method of treating aminoglycoside-resistant Mycobacterium 
tuberculosis (Mtb ), which involves administering an effec-
tive amount of a compound or composition as described 
25 herein. In some embodiments, the method also involves 
administering an aminoglycoside. In some embodiments, 
the aminoglycoside is kanamycin (KAN). In some embodi-
ments, the aminoglycoside is administered to a subject in 
30 
need of treatment for aminoglycoside-resistant Mtb. 
The presently-disclosed subject matter also includes a kit, 
which can include a compound or composition as described 
herein, packaged together with an aminoglycoside. 
BRIEF DESCRIPTION OF THE DRAWINGS 
35 
The novel features of the invention are set forth with 
particularity in the appended claims. A better understanding 
of the features and advantages of the present invention will 
be obtained by reference to the following detailed descrip-
40 tion that sets forth illustrative embodiments, in which the 
principles of the invention are used, and the accompanying 
drawings of which: 
FIG. 1 includes preparation schemes and structures of 
exemplary Eis inhibitor scaffolds according to the presently-
45 disclosed subject matter and discussed in Example 1. 
FIG. 2 includes structures of exemplary compounds 
according to the scaffolds set forth in FIG. 1. 
FIG. 3 includes structures of additional exemplary com-
pounds according to the scaffolds set forth in FIG. 1. 
50 FIG. 4 includes five panels, including models of com-
pound 2g (panels A and B) and la (panels C and D) in 
complex with a monomer of Eis_Mtb (panels A and C) or in 
complex with Eis (panels B and D), and the structures of 
compounds A and B (panel E) that were used to model 
55 compounds 2g and la in the active site of Eis. 
FIG. 5 includes representative IC50 curves for exemplary 
compounds according to the scaffolds set forth in FIG. 1. 
FIG. 6 includes preparation schemes and structures of 
exemplary Eis inhibitor scaffolds according to the presently-
60 disclosed subject matter and discussed in Example 2. 
FIG. 7 includes results of mammalian cytotoxicity studies 
of selected compounds (le*, li*, 2c*, 2h*, and 2i*) alone 
(represented as dark color columns) or in the presence of 50 
µg/mL ( equivalent to 86 µM) KAN (represented as light 
65 color colunms immediately to the right of the dark color 
colurmi of the corresponding compound in the absence of 
KAN) against A. A549, B. HEK-293, and C. J774A.1 cells. 
US 10,253,035 B2 
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and other embodiments, will be evident to those of ordinary 
skill in the art after a study of the information provided in 
this document. The information provided in this document, 
and particularly the specific details of the described exem-
FIG. 8 illustrates the inhibitor/aminoglycoside binding 
site showing the superimposition of Eis inhibitors and TOB 
from several crystal structures. The chemical structures of 
inhibitors 2k*, 13g, and 39, as well as of TOB are shown 
below the crystal structure. 
FIG. 9 includes results of a study showing cytotoxicity of 
KAN againstA549, HEK-293, and J774A.1 mammalian cell 
lines. 
5 plary embodiments, is provided primarily for clearness of 
understanding and no unnecessary limitations are to be 
understood therefrom. In case of conflict, the specification of 
this document, including definitions, will control. 
The presently-disclosed subject matter is illustrated by FIG. 10 includes a crystal structure of EisC204A-CoA-
inhibitor 2k* complex (PDB ID 5TVJ) (panel A), and a 
zoom-in view of the binding pocket of compound 2k* (panel 
B). 
FIG. 11 includes representative IC50 curves for exemplary 
compounds according to the scaffolds set forth in FIG. 6. 
FIG. 12 includes preparation schemes and structures of 
exemplary Eis inhibitor scaffolds according to the presently-
disclosed subject matter and discussed in Example 3. 
10 
specific but non-limiting examples throughout this descrip-
tion. The examples may include compilations of data that are 
representative of data gathered at various times during the 
course of development and experimentation related to the 
present invention(s). Each example is provided by way of 
explanation of the present disclosure and is not a limitation 
FIG. 13 includes a cartoon view of the crystal structure of 
Eis in complex with compound 39 and CoA, including the 
overall view of a monomer ofEis-CoA-inhibitor 39 complex 
(panel A), the zoomed-in view of the AG-binding site with 
the bound inhibitor (panel B), and a schematic of Eis-
inhibitor 39 contacts (panel C). 
15 thereon. In fact, it will be apparent to those skilled in the art 
that various modifications and variations can be made to the 
teachings of the present disclosure without departing from 
the scope of the disclosure. For instance, features illustrated 
or described as part of one embodiment can be used with 
20 another embodiment to yield a still further embodiment. 
All references to singular characteristics or limitations of 
the present disclosure shall include the corresponding plural 
characteristic(s) or limitation(s) and vice versa, unless oth-
erwise specified or clearly implied to the contrary by the FIG. 14 includes the crystal structure of Eis in complex 
with inhibitor 39 from this study and a previously published 
Eis inhibitor (labeled 13g in ref2) with an isothiazole S,S-
dioxide heterocyclic core obtained by superimposition of the 
crystal structures (panel A), and the zoomed-in view of the 
binding site with the bound inhibitors and TOB (panel B). 
25 context in which the reference is made. 
FIG. 15 includes representative IC50 curves for exemplary 30 
compounds according to the scaffolds set forth in FIG. 12. 
FIG. 16 includes a schematic representation of the win-
nowing of small organic molecules to 18 showing inhibition 
of both Eis enzymatic activity and growth of Mtb K204 in 
the presence of KAN (panel a), and structures of exemplary 
Eis inhibitor scaffolds according to the presently-disclosed 
subject matter and discussed in Example 4. 
FIG. 17 includes further structures of Eis inhibitor accord-
ing to the presently-disclosed subject matter and discussed 
in Example 4. 
FIG. 18 includes crystal structures ofEisC204A from Mtb 
in complex with 13g (a and b) and Ile (d and e), and the 
overall views of the Eis monomer with the inhibitors bound 
35 
40 
(a and c) and zoom-in views of the active site (band e) show 
that the inhibitors occupy a site overlapping with the amino- 45 
glycoside substrate-binding site; superposition of these 
respective inhibitor structures with the previously reported 
crystal structure of EisC204A in complex with CoA and 
tobramycin is shown in panels c and f. 
FIG. 19 includes representative IC50 curves for exemplary 50 
compounds according to the scaffolds set forth in FIGS. 16 
and 17. 
FIG. 20 includes a structural comparison of inhibitor 13g 
(panel a) and TOB bound in the active site of EisC204A 
(panel b ). 55 
FIG. 21 includes representative IC50 curves for exemplary 
compounds described in Example 5. 
FIG. 22 includes results of a study showing cytotoxicity 
of KAN against A549, HEK-293, and J774A.1 mammalian 
cell lines for exemplary compounds described in Example 5. 60 
DESCRIPTION OF EXEMPLARY 
EMBODIMENTS 
The details of one or more embodiments of the presently- 65 
disclosed subject matter are set forth in this document. 
Modifications to embodiments described in this document, 
All combinations of method or process steps as used 
herein can be performed in any order, unless otherwise 
specified or clearly implied to the contrary by the context in 
which the referenced combination is made. 
The presently-disclosed subject matter includes com-
pounds that are useful for inhibiting Eis. 
In some embodiments, the compound is 
o(i 
0 0 
00----ZOMe 00:0 N 
~o ~o 
R or R , 
wherein R is selected from the group cons1stmg of Ph, 
o-F-Ph, m-F-Ph, m-Cl-Ph, m-Br-Ph, m-OMe-Ph, p-F-Ph, 
p-Cl-Ph, p-Br-Ph, p-Me-Ph, naphthyl, Et, t-Bu, and m-NO2 -
Ph. 
In some embodiments, the compound is 
wherein R1 is selected from the group consisting of H, p-F, 
m,p-di-F; and R2 is selected from the group consisting ofH, 
o-F, m-F, m-Cl, m-Br, m-OH, m-OMe, p-F, p-Cl, p-Br, and 
p-Me. 
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In some embodiments, the compound is 
wherein R is selected from the group consisting of 
8 
-continued 
30 
wherein X i~ selected from the group consisting of H and 
40 Me, and Ar 1s selected from the group consisting of 
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OMe 
In some embodiments, the compound is 
wherein R1 is selected from the group consisting of 
F Cl 
2=1 
qc,qfu 
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and wherein R2 is selected from the group consisting of 
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wherein X is selected from the group consisting of 
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(vii) 
wherein X is selected from the group consisting of: 
12 
-continued 
10 
(viii) 
15 
20 
wherein X is selected from the group consisting of: 
25 
30 
(ix) 
35 
40 
wherein W, X, and Z are each independently selected from 
the group consisting of H and CH3 , and wherein Y is 
45 
selected from the group consisting of H, CH3 , 
US 10,253,035 B2 
13 
-continued 
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y 
wherein Y is selected from the group consisting of H and 
CH3 , and wherein Xis selected from the group consisting of 
CH3 , CH2 CH3 , (CH2 ) 2CH3 , 
10 
15 
20 
25 
30 
35 
40 
45 
50 
14 
(xi) 
wherein 
Y is selected from the group consisting of H, CH3 , 
CH2CH3 , and CH(CH3 ) 2 , and 
X is selected from the group consisting of CH2 CH3 , 
(xii) 
wherein 
W is selected from the group consisting of H, CH3 , F, Cl, 60 OCH3 , and OCH2CH3 , 
X is selected from the group consisting of H, Cl, Br, 
OCH3 , OCH2 CH3 , and OCH2O, 
Y is selected from the group consisting of H, CH3 , 
65 CH2CH3 , Br, F, Cl, OCH3 , OCH2CH3 , O(CH)(CH3 ) 2 , 
OCH2O, N(CH3 ) 2 , N(CH2CH3 ) 2 , and 
Z is selected from the group consisting of H and OCH3 ; 
US 10,253,035 B2 
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(xiii) 
wherein X is selected from the group consisting of 
wherein X is selected from the group consisting of 
(xiv) 
wherein 
Y is selected from the group consisting of N and C, and 
X is selected from the group consisting of 
wherein X is selected from the group consisting of: CH3 , 
CH2 CH3 , (CH2 ) 2 CH3 , CH(CH3 ) 2 , CH(CH3)CH2CH3 , 
C(CH3 ) 3 , (CH2 ) 2 CH(CH3 ) 2 , (CH2 ) 2OCH3 , (CH2 ) 3OCH3 , 
(CH2 ) 3OCH2 CH3 , (CH2 ) 3 OCH(CH3 ) 2 , 
25 
30 
35 
40 
45 
16 
(xvi) 
wherein 
V is selected from the group cons1stmg of H, CH3 , 
CH2CH3 , F, Cl, Br, OCH3 , and OCH2 CH3 , 
W is selected from the group consisting of H, CH3 , F, Cl, 
CH2CH3 , SCH3 , OCH3 , OCH2 O, and CO2 CH3 , 
X is selected from the group consisting of H, CH3 , 
CH2CH3 , CH(CH3 ) 2 , F, Cl, Br, OCH3 , OCH2O, OCH2CH3 , 
Y is selected from the group consisting of H, CH3 , F, Cl, 
65 OCH3 , CO2 CH3 , Br, CH2CH3 , and OCH2 CH3 , 
Z is selected from the group consisting of H, CH3 , and 
CH2CH3 , 
US 10,253,035 B2 
(xvii) 
wherein 
17 
X y 
N~' tNH-
X is selected from the group consisting of H and CH3 , 
Yis selected from the group consisting ofH, CH3 , Cl, and 
Br, and 
Z is selected from the group consisting ofH and CH3 ; and 
(xviii) 
wherein X is selected from the group consisting of 
and 
In some embodiments, the compound is 
where R1 -R4 are selected to provide a compound selected 
from the group consisting of: 
10 
15 
20 
25 
30 
35 
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50 
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In some embodiments, the compound is 
50 
CC~~ 0 
\). 
R 
65 wherein R is selected from the group consisting of 4-Cl, 4-F, 
4-Br, 3-Cl, 3-F, and H; and Ar is selected from the group 
consisting of Ph, 3-Py, 2-Py, 4-Py, and Ph. 
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In some embodiments, the compound is 
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from the group consisting of: 
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The presently-disclosed subject matter further includes 
methods or inhibiting Eis and methods of treating amino-
glycoside-resistant Mtb. In some embodiments the method 
20 involves administering a compound or composition as dis-
closed herein. In some embodiments, the method involves 
administering a compound or composition to a subject in 
need of treatment for aminoglycoside-resistant Mtb. In some 
embodiments, the method further includes administering an 
aminoglycoside. In some embodiments the aminoglycoside 
is kanamycin (KAN). 
The presently-disclosed subject matter further includes 
composition that include at least one compound disclosed 
herein as an Eis inhibitor, and an aminoglycoside. In some 
30 embodiments the aminoglycoside is kanamycin (KAN). 
The presently-disclosed subject matter further includes 
kits comprising at least one compound disclosed herein as an 
Eis inhibitor, packaged together with an aminoglycoside. In 
some embodiments the aminoglycoside is kanamycin 
35 (KAN). 
The presently disclosed subject matter includes identified 
potent inhibitors of Eis enzymatic activity with resulting 
sensitization of KAN-resistant Mtb cells, in which the 
resistance to KAN is caused by Eis upregulation. The 
40 inhibitors bind in the AG binding pocket blocking the access 
of AGs to the active site of the enzyme. The inhibitor 
binding is accompanied by induced-fit conformational 
changes of the protein. These compounds have a great 
45 
50 
potential for further development as KAN adjuvants in Mtb. 
The presently-disclosed subject matter includes novel 
small molecule compositions, and small molecule compo-
sitions useful as inhibitors of Eis enzymatic activity. In some 
embodiments, the inhibitors can effectively overcome 
kanamycin resistance in strains of Mtb. 
The presently-disclosed subject matter further includes a 
pharmaceutical composition including a small molecule, as 
described herein, and a suitable pharmaceutical carrier. The 
presently-disclosed subject matter also includes a method of 
treating a bacterial infection comprising administering to an 
55 individual an effective amount of a small molecule Eis 
inhibitor, as disclosed herein. In some instances, the phar-
maceutical composition is administered with an aminogly-
coside. In some instances the aminoglycoside is Kanamycin. 
Methods of treating kanamycin resistance are also dis-
60 closed herein, comprising administering a small molecule 
composition disclosed herein. Also provided are methods of 
treating tuberculosis comprising administering the Eis 
inhibitors disclosed herein with kanamycin. 
In some embodiments, a method is provided for treating 
65 antibiotic resistance and/or inhibiting Eis enzymatic activity 
in a cell. In some embodiment the method includes contact-
ing the cell with compounds disclosed herein. The term 
US 10,253,035 B2 
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"contacting" as used herein refers to any means by which the 
compound is brought into sufficient proximity and/or in 
direct contact with a cell such that the cell is capable of 
receiving the compound. For instance, in some embodiments 
contact refers to coating or otherwise exposing a cell to the 
compound. In some embodiments contact refers to culturing 
a cell in a solution that includes the compound. In other 
embodiments the cell is within a subject, and contact refers 
to administering a compound to the subject such that a cell 
within the subject is capable of receiving the novel small 
molecule compounds. In some embodiments, such methods 
can include further administration of an antibiotic at the 
same time as the administration of the compound, or prior to 
or subsequent to the administration of compound. In some 
embodiments, the antibiotic is kanamycin. The presently-
disclosed subject matter further includes composition that 
include at least one compound disclosed herein as an Eis 
inhibitor, and an aminoglycoside. In some embodiments the 
aminoglycoside is kanamycin (KAN). In some embodi-
ments, the cell exhibits resistance to kanamycin. In some 
embodiments, said cell is within a subject diagnosed with 
tuberculosis. 
While the following terms used herein are believed to be 
well understood by one of ordinary skill in the art, defini-
tions are set forth to facilitate explanation of the presently-
disclosed subject matter. 
The terms "polypeptide", "protein", and "peptide", which 
are used interchangeably herein, refer to a polymer of the 
protein amino acids, or amino acid analogs, regardless of its 
size or function. Although "protein" is often used in refer-
ence to relatively large polypeptides, and "peptide" is often 
used in reference to small polypeptides, usage of these terms 
in the art overlaps and varies. The term "polypeptide" as 
used herein refers to peptides, polypeptides, and proteins, 
unless otherwise noted. The terms "protein", "polypeptide", 
and "peptide" are used interchangeably herein when refer-
ring to a gene product. Thus, exemplary polypeptides 
include gene products, naturally occurring proteins, 
homologs, orthologs, paralogs, fragments and other equiva-
lents, variants, and analogs of the foregoing. 
Unless otherwise indicated, the term "administering" is 
inclusive of all means known to those of ordinary skill in the 
44 
sired symptoms, but is generally insufficient to cause 
adverse side effects. The specific therapeutically effective 
dose level for any particular patient will depend upon a 
variety of factors including the disorder being treated and 
5 the severity of the disorder; the specific composition 
employed; the age, body weight, general health, sex and diet 
of the patient; the time of administration; the route of 
administration; the rate of excretion of the specific com-
pound employed; the duration of the treatment; drugs used 
10 in combination or coincidental with the specific compound 
employed and like factors well known in the medical arts. 
For example, it is well within the skill of the art to start doses 
of a compound at levels lower than those required to achieve 
15 the desired therapeutic effect and to gradually increase the 
dosage until the desired effect is achieved. If desired, the 
effective daily dose can be divided into multiple doses for 
purposes of administration. Consequently, single dose com-
positions can contain such amounts or submultiples thereof 
20 to make up the daily dose. The dosage can be adjusted by the 
individual physician in the event of any contraindications. 
Dosage can vary, and can be administered in one or more 
dose administrations daily, for one or several days. Guidance 
can be found in the literature for appropriate dosages for 
25 given classes of pharmaceutical products. In further various 
aspects, a preparation can be administered in a "prophylac-
tically effective amount"; that is, an amount effective for 
prevention of a disease or condition. 
Additionally, the terms "subject" or "subject in need 
30 thereof' refer to a target of administration, which optionally 
displays symptoms related to a particular disease, pathologi-
cal condition, disorder, or the like. The subject of the herein 
disclosed methods can be a vertebrate, such as a manimal, a 
35 fish, a bird, a reptile, or an amphibian. Thus, the subject of 
the herein disclosed methods can be a human, non-human 
primate, horse, pig, rabbit, dog, sheep, goat, cow, cat, guinea 
pig or rodent. The term does not denote a particular age or 
sex. Thus, adult and newborn subjects, as well as fetuses, 
40 whether male or female, are intended to be covered. A 
patient refers to a subject afflicted with a disease or disorder. 
The term "subject" includes human and veterinary subjects. 
art for providing a preparation to a subject, including admin-
istration by inhalation, nasal administration, topical admin-
istration, intravaginal administration, ophthalmic adminis- 45 
tration, intraaural administration, intracerebral 
administration, intravitreous administration, intracameral 
administration, posterior sub-Tenon administration, poste-
rior juxtascleral administration, subretinal administration, 
suprachoroidal administration, cell-based administration or 50 
production, rectal administration, and parenteral administra-
tion, including injectable such as intravenous administra-
tion, intra-arterial administration, intramuscular administra-
tion, and/or subcutaneous administration. Administration 
can be continuous or intermittent. A preparation can be 55 
administered therapeutically; that is, administered to treat an 
existing condition of interest. A preparation can be admin-
istered prophylactically; that is, administered for prevention 
In some embodiments the subject in need thereof will be 
suffering or will have been diagnosed tuberculosis and/or 
related diseases, disorders, pathologies, or conditions. 
As used herein, the terms "treatment" or "treating" relate 
to any treatment of a condition of interest, including but not 
limited to prophylactic treatment and therapeutic treatment. 
As such, the terms treatment or treating include, but are not 
limited to: preventing a condition of interest or the devel-
opment of a condition of interest; inhibiting the progression 
of a condition of interest; arresting or preventing the devel-
opment of a condition of interest; reducing the severity of a 
condition of interest; ameliorating or relieving symptoms 
associated with a condition of interest; and causing a regres-
sion of the condition of interest or one or more of the 
symptoms associated with the condition of interest. 
Unless defined otherwise, all technical and scientific 
terms used herein have the same meaning as commonly 
understood by one of ordinary skill in the art to which the 
presently-disclosed subject matter belongs. Although any 
of a condition of interest. 
In some embodiments a subject will be administered an 60 
effective amount of at least one compound and/or compo-
sition provided in the present disclosure. In this respect, the 
term "effective amount" refers to an amount that is sufficient 
methods, devices, and materials similar or equivalent to 
those described herein can be used in the practice or testing 
of the presently-disclosed subject matter, representative to achieve the desired result or to have an effect on an 
undesired condition. For example, a "therapeutically effec-
tive amount" refers to an amount that is sufficient to achieve 
the desired therapeutic result or to have an effect on unde-
65 methods, devices, and materials are now described. 
Following long-standing patent law convention, the terms 
"a", "an", and "the" refer to "one or more" when used in this 
US 10,253,035 B2 
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application, including the claims. Thus, for example, refer-
ence to "an enzyme" includes a plurality of such enzymes, 
and so forth. 
Unless otherwise indicated, all numbers expressing quan-
tities of ingredients, properties such as reaction conditions, 
and so forth used in the specification and claims are to be 
understood as being modified in all instances by the term 
"about". Accordingly, unless indicated to the contrary, the 
numerical parameters set forth in this specification and 
claims are approximations that can vary depending upon the 
desired properties sought to be obtained by the presently-
disclosed subject matter. 
As used herein, the term "about," when referring to a 
value or to an amount of mass, weight, time, volume, 
concentration or percentage is meant to encompass varia-
tions of in some embodiments ±5%, in some embodiments 
±1%, in some embodiments ±0.5%, in some embodiments 
±0.1%, and in some embodiments ±0.01% from the speci-
fied amount, as such variations are appropriate to perform 
the disclosed method. 
As used herein, ranges can be expressed as from "about" 
one particular value, and/or to "about" another particular 
value. It is also understood that there are a number of values 
disclosed herein, and that each value is also herein disclosed 
46 
be brought about by the inclusion of agents, such as alumi-
num monostearate and gelatin, which delay absorption. 
Injectable depot forms are made by forming microencapsule 
matrices of the drug in biodegradable polymers such as 
5 polylactide-polyglycolide, poly(orthoesters) and poly(anhy-
drides). Depending upon the ratio of drug to polymer and the 
nature of the particular polymer employed, the rate of drug 
release can be controlled. Depot injectable formulations are 
also prepared by entrapping the drug in liposomes or micro-
IO emulsions which are compatible with body tissues. The 
injectable formulations can be sterilized, for example, by 
filtration through a bacterial-retaining filter or by incorpo-
rating sterilizing agents in the form of sterile solid compo-
15 sitions which can be dissolved or dispersed in sterile water 
or other sterile injectable media just prior to use. Suitable 
inert carriers can include sugars such as lactose. 
Suitable formulations include aqueous and non-aqueous 
sterile injection solutions that can contain antioxidants, 
20 buffers, bacteriostats, bactericidal antibiotics and solutes 
that render the formulation isotonic with the bodily fluids of 
the intended recipient; and aqueous and non-aqueous sterile 
suspensions, which can include suspending agents and 
thickening agents. 
as "about" that particular value in addition to the value itself. 25 
For example, if the value "10" is disclosed, then "about 10" 
The compositions can take such forms as suspensions, 
solutions or emulsions in oily or aqueous vehicles, and can 
contain formulatory agents such as suspending, stabilizing 
and/or dispersing agents. Alternatively, the active ingredient 
can be in powder form for constitution with a suitable 
is also disclosed. It is also understood that each unit between 
two particular units are also disclosed. For example, if 10 
and 15 are disclosed, then 11, 12, 13, and 14 are also 
disclosed. 
As will be recognized by one of ordinary skill in the art, 
the terms "reduce", "reducer", "reduction", "reducing", 
"suppression," "suppressing," "suppressor," "inhibition," 
"inhibiting" or "inhibitor" do not refer to a complete elimi-
nation of angiogenesis in all cases. Rather, the skilled artisan 
will understand that the term "reducing", "suppressing" or 
"inhibiting" refers to a reduction or decrease in a particular 
condition. Such reduction or decrease can be determined 
relative to a control. In some embodiments, the reduction or 
decrease relative to a control can be about a 1, 2, 3, 4, 5, 6, 
7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 
24,25, 26,27,28, 29, 30,31,32, 33,34,35,36, 37,38,39, 
40,41, 42,43,44, 45, 46,47,48, 49, 50, 51, 52, 53, 54, 55, 
30 
vehicle, e.g., sterile pyrogen-free water, before use. 
The formulations can be presented in unit-dose or multi-
dose containers, for example sealed ampoules and vials, and 
can be stored in a frozen or freeze-dried (lyophilized) 
35 condition requiring only the addition of sterile liquid carrier 
immediately prior to use. 
For oral administration, the compositions can take the 
form of, for example, tablets or capsules prepared by a 
conventional technique with pharmaceutically acceptable 
56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 
72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 
88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% 
decrease. 
40 excipients such as binding agents ( e.g., pregelatinized maize 
starch, polyvinylpyrrolidone or hydroxypropyl methylcellu-
lose ); fillers ( e.g., lactose, microcrystalline cellulose or 
calcium hydrogen phosphate); lubricants (e.g., magnesium 
stearate, talc or silica); disintegrants (e.g., potato starch or 
45 sodium starch glycolate); or wetting agents (e.g., sodium 
lauryl sulphate). The tablets can be coated by methods 
known in the art. 
As described herein, the presently-disclosed subject mat-
ter further includes pharmaceutical compositions compris-
ing at least one enzyme described herein together with a 50 
pharmaceutically acceptable carrier. 
The term "pharmaceutically acceptable carrier" refers to 
sterile aqueous or nonaqueous solutions, dispersions, sus-
pensions or emulsions, as well as sterile powders for recon-
stitution into sterile injectable solutions or dispersions just 55 
prior to use. Proper fluidity can be maintained, for example, 
by the use of coating materials such as lecithin, by the 
maintenance of the required particle size in the case of 
dispersions and by the use of surfactants. These composi-
tions can also contain adjuvants such as preservatives, 60 
wetting agents, emulsifying agents and dispersing agents. 
Prevention of the action of microorganisms can be ensured 
by the inclusion of various antibacterial and antifungal 
agents such as paraben, chlorobutanol, phenol, sorbic acid 
and the like. It can also be desirable to include isotonic 65 
agents such as sugars, sodium chloride and the like. Pro-
longed absorption of the injectable pharmaceutical form can 
Liquid preparations for oral administration can take the 
form of, for example, solutions, syrups or suspensions, or 
they can be presented as a dry product for constitution with 
water or other suitable vehicle before use. Such liquid 
preparations can be prepared by conventional techniques 
with pharmaceutically acceptable additives such as suspend-
ing agents ( e.g., sorbitol syrup, cellulose derivatives or 
hydrogenated edible fats); emulsifying agents (e.g. lecithin 
or acacia); non-aqueous vehicles (e.g., almond oil, oily 
esters, ethyl alcohol or fractionated vegetable oils); and 
preservatives ( e.g., methyl or propyl-p-hydroxybenzoates or 
sorbic acid). The preparations can also contain buffer salts, 
flavoring, coloring and sweetening agents as appropriate. 
Preparations for oral administration can be suitably formu-
lated to give controlled release of the active compound. For 
buccal administration the compositions can take the form of 
tablets or lozenges formulated in conventional manner. 
The compositions can be formulated as eye drops. For 
example, the pharmaceutically acceptable carrier may com-
prise saline solution or other substances used to formulate 
US 10,253,035 B2 
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eye drop, optionally with other agents. Thus, eye drop 
formulations permit for topical administration directly to the 
eye of a subject. 
The compositions can also be formulated as a preparation 
for implantation or injection. Thus, for example, the com- 5 
pounds can be formulated with suitable polymeric or hydro-
phobic materials (e.g., as an emulsion in an acceptable oil) 
or ion exchange resins, or as sparingly soluble derivatives 
(e.g., as a sparingly soluble salt). The compounds can also 
be formulated in rectal compositions, creams or lotions, or 10 
transdermal patches. 
The presently-disclosed subject matter further includes a 
kit that can include an enzyme and/or a pharmaceutical 
composition as described herein, packaged together with a 15 
device useful for administration of the compound or com-
position. As will be recognized by those or ordinary skill in 
the art, the appropriate administration-aiding device will 
depend on the formulation of the compound or composition 
that is selected and/or the desired administration site. For 20 
example, if the formulation of the compound or composition 
is appropriate for injection in a subject, the device could be 
a syringe. For another example, if the desired administration 
site is cell culture media, the device could be a sterile 
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EXAMPLES 
Example 1 
This Example related to Eis inhibitors having the follow-
ing scaffolds: the methyl 4H-furo[3,2-b ]pyrrole-5-carboxy-
late (scaffold 1) and the 3-(1,3-dioxolano )-2-indolinone 
(scaffold 2) identified by high-throughput screening HTS, 
the synthesis of 13 and 14 analogues of these scaffolds, 
respectively, and their biochemical and biological testing. 
First, we screened -123,000 small molecules for inhibi-
tion of KAN acetylation by Eis_Mtb. The HTS yielded two 
promising scaffolds 1 and 2 (FIG. 1). Sixty compounds 
containing scaffold 1 (FIG. 2) were present in the HTS 
library. In these sixty compounds, the pyrrole ring was 
decorated with different groups including alkyl chains, aryl 
and oxazole rings, as well as amides. Fifty-nine of these 
scaffold 1 molecules did not inhibit Eis_Mtb, however 
pipette. 
The presently-disclosed subject matter includes novel 
small molecules. Also disclosed are small molecules that 
inhibit Eis. Small molecule Eis inhibitors disclosed herein 
aid in reducing KAN resistance and/or restoring KAN 
susceptibility in Mycobacterium tuberculosis. The pres-
ently-disclosed subject matter further includes a pharmaceu-
tical composition including a small molecule inhibitor, as 
described herein, and a suitable pharmaceutical carrier, 
optionally administered with Kanamycin. The presently-
disclosed subject matter further includes a method of treat-
ing tuberculosis, including aminoglycoside resistant tuber-
culosis, comprising administering to an individual an 
effective amount of a small molecule Eis inhibitor, as 
disclosed herein, to inhibit the Eis acetyltransferase of 
Mycobacterium tuberculosis and reduce KAN resistance 
compound la (FIG. 1, also labeled as 4kk in FIG. 2) 
displayed some inhibition in the HTS. Because la contained 
an aryl ketone group, we opted to synthesize la along with 
12 additional analogues (1 b-lm) comprised of different aryl 
groups (FIG. 1). For scaffold 2, ten compounds with differ-
ent groups attached to the indolinone ring were in the HTS 
25 library (FIG. 3). A hydrogen (Sa), an alkyl (Sb), an alkyl 
ketone (Sc), a carboxylic acid (9a), or an amide (9b) sub-
stituent resulted in no Eis_Mtb inhibitory activity. Similarly 
to the scaffold 1 analogues, aryl ketones of scaffold 2 (Sf-Sh) 
displayed Eis_Mtb inhibition, with the exception of the 
30 trifluoromethyl substituted aryl ketones (Sd and Se). Three 
compounds synthesized from scaffold 2 (Sf-Sh, FIG. 3) were 
found to be active. These and 11 of their analogues con-
taining different aryl substituents for further study (Note: 
Sf-Sh are numbered 2g-2i in FIG. 1 to represent the scaffold 
35 2 series). 
Compound la and 12 analogues (lb-lm) as well as 14 
analogues for scaffold 2 (2a-2n) with different R substituents 
were synthesized for structure-activity-relationship (SAR) 
analysis of Eis_Mtb inhibition in vitro and in cellulo (FIG. 
40 1). All new compounds were characterized by 1H, 13C NMR 
(FIGS. S5-S56), mass spectrometry, and were established to 
be ;;,;95% pure by HPLC prior to further testing. and/or restore KAN susceptibility. 
In certain embodiments, the present disclosure further 
provides a method of treating, preventing and/or reducing 
kanamycin resistance and/or restoring KAN susceptibility in 45 
Mycobacterium tuberculosis. The method comprises at least 
the step of administering an effective amount of a small 
molecule inhibitor provided in the present disclosure to a 
subject. In some embodiments, the subject is in need of 
treatment. In some instances, the Mycobacterium tubercu- 50 
losis strain is Mtb K204 or H37Rv. In some embodiments, 
the small molecule is administered with an aminoglycoside, 
for example, kanamycin. In some embodiments, the treat-
ment reduces and/or eliminates the Eis-mediated KAN resis-
Cpd 
la 
lb 
tance of Mycobacterium tuberculosis. 55 le 
ld 
le 
lf 
lg 
lh 
Additionally, in certain embodiments, the inhibitors of the 
present disclosure have a Mtb strain K204 MIC KAN value of 
less than about 5.0 µg/mL, of less than about 2.5 µg/mL, or 
less than about 1.25 µg/mL. In other embodiments, the 
li inhibitors have a MICKAN value of less than about 0.625 60 lj 
µg/mL for Mycobacterium tuberculosis (Mtb) strain H37Rv. lk 
The presently-disclosed subject matter is further illus- 11 
trated by the following specific but non-limiting examples. 
The following examples may include compilations of data 
that are representative of data gathered at various times 
during the course of development and experimentation 
related to the present invention. 
lm 
2a 
2b 
65 2c 
2d 
TABLE 1 
IC50 values against purified Eis_Mtb and MIC values against 
Mtb H37Rv and Mtb K204 witb tbe compounds at tbe 
concentrations specified. 
H37Rv K204 
Concentration MICKAN MICKAN 
IC50 (µM)" tested (µMl (µg/mL)" (µg/mL/ 
,;1.25 a,)0, 10 
3 ± 1 100 ,;1.25 5, 10 
2.9 ± 0.9 100 ,;1.25 10, 10 
0.16 ± 0.07 15.5 ,;1.25 10, 10 
0.25 ± 0.08 25.1 ,;1.25 a,)0, 10 
0.5 ± 0.2 52.6 ,;1.25 a,)0, 10 
>200 100 ,;1.25 a,)0, 10 
0.3 ± 0.1 33.9 ,;1.25 10, 10 
0.6 ± 0.3 64.5 ,;1.25 10, a,)0 
>200 100 ,;1.25 a,)0, a,)0 
5.8 ± 1.8 100 ,;1.25 5, 10 
>200 100 ,;1.25 10, 10 
>200 100 ,;1.25 a,)0, 10 
>200 100 ,;1.25 a,)0, 10 
0.33 ± 0.16 32.6 ,;1.25 5, 5 
23 ± 10 100 ,;1.25 10, 10 
0.30 ± 0.08 29.7 ,;1.25 5, 2.5 
0.015 ± 0.005 1.5 ,;1.25 a,)0, 10 
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TABLE I-continued 
50 
while it displayed limited Eis inhibition in the HTS, which 
could indicate that the compound in the HTS library was not 
completely pure. We also found that the p-methyl derivative 
2j displayed a 100-fold decrease in Eis inhibitory activity 
Cpd 
2e 
2f 
2g 
2h 
2i 
2j 
2k 
21 
2m 
2n 
IC50 values against purified Eis_Mtb and MIC values against 
Mtb H37Rv and Mtb K204 witb tbe compounds at tbe 
concentrations specified. 
H37Rv K204 
Concentration MICKAN MICKAN 
ICso (µM)" tested (µM/ (µg/mL)" (µg/mL/ 
0.54 ± 0.25 54.2 ,;1.25 10, 5 
5 (IC50=8.7±2.2 µM) from 2g and in combination with KAN 
resulted in almost the same KAN MIC (5-10 µg/mL) against 
KAN-resistant Mtb as 2g did. The non-substituted counter-
part of parent 2g, derivative 2a, displayed weaker Eis 
inhibitory activity (IC50=0.33±0.16 µM) and improved the 
>200 100 
0.09 ± 0.03 8.9 
2.2 ± 0.7 100 
>200 100 
8.7 ± 2.2 100 
>200 100 
,;1.25 ;,10, 10 
,;1.25 5, 5 
,;1.25 10, 5 
,;1.25 ;,10, 10 
,;1.25 5, 10 
,;1.25 10, 10 
10 activity of KAN against Mtb K204 (MICKAN=5 µg/mL). We 
also synthesized the m-fluoro, m-chloro, and m-bromo 
derivatives 2c, 2d, and 2e. The m-chloro substituted 2d 
showed the same inhibitory activity as that of 2g, but did not 
sensitize Mtb K204 to KAN (MICKA?-10 µg/mL). The 
>200 100 ,;1.25 ;,10, 10 
>200 100 ,;1.25 ;,10, 10 
1.2 ± 0.4 100 ,;1.25 10, 5 
aIC50 against purified Eis_Mtb enzyme, 
bConcentrations of Eis inhibitor in the MIC assays. At these concentrations, these 
compounds did not inhibit the growth ofMtb H37Rv or that ofMtb K204 when tested in 
the absence of KAN. Concentrations of Eis inhibitors were l00x their IC50 when IC50 <l 
15 m-fluoro and m-bromo substituted 2c and 2e resulted in a 3-
and 5-fold worse Eis inhibitory activity (IC50=0.30±0.08 
and 0.54±0.25 µM), respectively. When used with the 
m-bromo-substituted 2e, KAN had an MIC of 5-10 µg/mL 
against Mtb K204. However, when used with the m-fluoro 
f?IM, or lQQf?IM for IC50 >11 M. 
c Activity of KAN against Mtb H37Rv. 
d Activity of KAN against Mtb K204. 
For c and d, results are from two experiments. 
20 substituted 2c, KAN displayed a better MIC value of 2.5-5 
µg/mL. As observed with scaffold 1, the presence of 
m-methoxy-phenyl, naphthyl, ethyl, and t-butyl groups in 
scaffold 2 resulted in molecules that were completely inac-
tive (IC50>200 µM and MICKA?-10 µg/mL against Mtb 
K204). For scaffold 2, we also synthesized a m-nitro sub-
stituted compound (2n) to investigate the potential effect of 
a strong electron-withdrawing group on Eis inhibitory activ-
ity. Compound 2n was less active (IC50=1.2±0.4 µM) than 
2g, but it sensitized Mtb K204 to KAN (MICKAN=5-10 
30 µg/mL). The absence of antibacterial activity of these com-
pounds when used alone along with a general correlation 
between IC50 and MIC values indicated that inhibition of Eis 
by these compounds is the main mechanism of sensitization 
to KAN. 
We evaluated biochemical (inhibition (IC50) of purified 25 
Eis_Mtb enzyme) and biological (effect on the KAN MIC 
values for KAN-sensitive Mtb H37Rv and KAN-resistant 
Mtb K204 cells) properties of these compounds, in parallel 
(Table 1; FIG. 5). The freshly synthesized la, which dis-
played some inhibition of Eis_Mtb in the HTS campaign, 
was confirmed to be a good Eis_Mtb inhibitor in vitro 
(IC50=3±1 µM). In the presence of la, KAN displayed an 
MIC of 5-10 µg/mL against Mtb K204. Having confirmed 
the weak inhibitory activity of la, we explored the effect of 
substitution on the phenyl ring on the aryl ketone part of 35 
scaffold 1. Ortho substitution, as in 1 b with a o-fluoro 
substituent, resulted in almost the same Eis_Mtb inhibitory 
activity (IC50=2.9±0.9 µM) as that for the parent la. KAN 
MIC against Mtb K204 was unaffected by lb (MICKAN=l0 
µg/mL). To establish if meta or para substitution would be 40 
more favorable than ortho substitution, we generated com-
pounds le-lj. For both meta and para substitutions, bulkier 
substituents led to weaker Eis_Mtb inhibition (IC50>200 µM 
for m-methoxy (lf) and p-bromo (li) compared to 
IC50=0.16±0.07 and 0.3±0.1 µM for m-fluoro (le) and 45 
p-fluoro (lg), respectively). Most of these derivatives (le-li) 
did not improve KAN activity against Mtb K204. The 
p-methyl derivative lj displayed almost the same Eis_Mtb 
inhibitory activity (IC50=5.8±1.8 µM) and MIC value 
against Mtb K204 as that of la. We generated lk (naphthyl 50 
substituted) with the hope of strengthening any possible Jt-Jt 
interaction between the inhibitor and the AG-binding site of 
the Mtb Eis. This compound was found to be completely 
inactive (IC50>200 µMand MICKAN=l0 µg/mL against Mtb 
K204). Finally, replacing the phenyl ring with alkyl chains 55 
(ethyl (11) and t-butyl (lm)) did not improve the Eis inhi-
bition or MICKAN for K204 Mtb. 
For scaffold 2, compound 2g-2i, which displayed Eis_Mtb 
inhibition in the HTS, were freshly synthesized. The 
p-fluoro substituted 2g displayed good Eis inhibitory activ- 60 
ity (IC50=0.09±0.03 µM) and when used in combination 
with KAN resulted in MICKAN of 5 µg/mL against K204 
Mtb. The p-chloro substituted 2h was less active 
(IC50=2.2±0.7 µM) than the p-fluoro substituted 2g and did 
not sensitize Mtb K204 to KAN (MICKAN=5-10 g/mL). The 65 
p-bromo substituted 2i was found to be completely inactive 
(IC50>200 µMand MICKA?-10 µg/mL against Mtb K204), 
To investigate the selectivity of our inhibitors towards 
Eis_Mtb, we tested two of our derivatives, one from each 
series, le and 2c, against three other AAC enzymes with 
different acetylation regiospecificities: AAC(2')-Ic from 
Mtb, 5 AAC(3)-IV from E. coli, 12 and AAC( 6')-Ie/ APH(2")-
Ia from Staphylococcus aureus. 13 Similarly to other known 
non-Eis AACs, these three enzymes were previously shown 
to be strictly regiospecific, but, like Eis, each enzyme was 
capable of acetylating structurally distinctAGs.40 Neither le 
nor 2c inhibited KAN acetylation by these three AACs at 
concentrations as high as 200 µM, which indicated that our 
compounds were highly selective against Eis_Mtb. 
To explain the results of our SAR study, we used previ-
ously published crystal structures of ternary Eis_Mtb-CoA-
compound A (13g in ref14; PDB ID 5EC4) and B (llc in 
ref14; PDB ID 5EBV) complexes to model our inhibitors la 
and 2g in a position similar to that of inhibitors A and B 
(FIG. 4). Without the crystal structures, de nova computa-
tional modeling of and screening for Eis inhibitors, includ-
ing pharmacophore-based computer modeling, are invali-
dated by significant conformational changes in the Eis active 
site upon inhibitor binding.13 The inhibitors occupy the site 
overlapping with the AG-binding site of Eis. The models 
show that the cores of inhibitors la and 2g are surrounded 
by the side chains of hydrophobic amino acid residues 
(Trp36, the aliphatic part of Glu401, Ile28, Phe24, and 
Val400). The cores stack with the indole ofTrp36, and in the 
orthogonal direction they are sandwiched between Glu401, 
the Eis C-terminus on one side and Ile28 on the other. The 
acetophenone rings of both series 1 and 2 with different 
substituents stack with Phe84, explaining why replacing 
these aromatic rings with alkyl chains resulted in a loss of 
activity for 11, lm, 21, and 2m. The acetophenone rings are 
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also surrounded by several hydrophobic amino acid residues 
(Phe84, Trp36, Met65, Ala33). Therefore putting a polar 
methoxy group in this hydrophobic environment would 
likely destabilize Eis binding, explaining the IC50 values of 
>200 µM for if and 2f. The para position of the acetophenone 5 
rings is flanked by Phe84 and Trp36, and it is -5 A away 
from Trp13 and Met65, explaining why the bulkier bromo 
substituents of li and 2i resulted in lower Eis inhibitory 
activity, whereas the small fluoro substituents of 1 g and 2g 
improved Eis inhibitory activity. The ortho position of the 10 
acetophenone rings is flanked by Phe402, explaining why an 
ortho substituent, as in 1 b and 2b, resulted in a loss of Eis 
inhibition. The models shows that there is space for small 
substitution in the meta position of the acetophenone rings 
(a -5 A-gap). Small substituents such as the fluoro and 15 
chloro of le, ld, 2c and 2d fit well in the cavity, explaining 
why these compounds displayed good Eis inhibition. How-
ever, bulkier substituents such as the bromo of le and 2e or 
the nitro of 2n are too big to be accommodated at this site 
and would clash with Eis residues, accounting for the poor 20 
Eis inhibition by these compounds. We also determined that 
the calculated Log P values of all compounds are in the 
desirable range (0.98-3.75). 
In sum, we have discovered two scaffolds with Eis 
inhibitory activity. From 27 synthesized analogues of these 25 
scaffolds with the variable acetophenone appendage, we 
identified potent inhibitors of Eis. Growth inhibition studies 
of our inhibitors in combination with KAN in KAN-suscep-
tible Mtb H37Rv (MICKANsl .25 µg/mL) and KAN-resistant 
Mtb K204 (MICKA?-10 µg/mL) showed that some of our 30 
inhibitors were able to sensitize Mtb K204 to KAN. Smaller 
52 
concentration, essentially making resistant Mtb isolate 
KAN-susceptible, such inhibitors could play a crucial role in 
recovering KAN as a treatment option. 
Example 2 
This Example related to Eis inhibitors having the scaf-
folds as set forth in FIG. 6 and reports report the chemical 
synthesis of various compounds, along with their biochemi-
cal and biological studies. Among compounds in this series, 
we have generated novel and promising Eis inhibitors that 
not only efficiently inhibit the purified enzyme, but also 
restore KAN sensitivity of KAN-resistant Mtb bacteria. We 
also present a crystal structure of Eis in complex with CoA 
and one potent inhibitor ( compound 2k*), which explains 
the structure-activity relationship (SAR). 
Compound la* and 47 additional analogues la-3k with 
different R1 and R2 substituents on the two phenyl rings and 
either a fully aromatized (indicated by an asterisk after the 
compound number) or a non-aromatized pyrrolo[l ,5-a ]pyra-
zine core were generated for a thorough SAR analysis of Eis 
inhibition (Scheme lB). The synthesis of all compounds 
started with a reaction between the commercially available 
pyrrole and 2-chloroethylamine, which afforded compound 
4 in quantitative yield. Compound 4 was reacted with 
different substituted benzoyl chlorides to obtain amides 5-7 
in 66-71 % yields. The resulting amides were mixed with 
phosphorus(V) oxychloride to generate cyclized products 
8-10. Then, compounds 8-10 were reacted with various 
substituted 2-bromoacetophenones 
to obtain the desired non-aromatized products la-k, 2a-k, 
and 3a,d,h,k. In order to generate the aromatized counter-
parts of these products, compounds 8 and 9 were first 
aromatized in the presence of Pd/C to generate molecules 11 
substituents, like hydrogen and fluorine, yielded the best 
compounds. In contrast, larger substituents, such as bromo 
or methoxy dramatically decreased the potency of the com-
pounds. The best compound identified was 2c with the 
3-(1,3-dioxolano )-2-indolinone core and a m-fluoro-phenyl 
substituent. This compound when used in combination with 
KAN reduced the MICKAN for KAN-resistant Mtb to 2.5-5 
µg/mL. While CLSI recommends MICKAN of 5 µg/mL on 
Middlebrook 7H10 agar, it has no recommendation for 
susceptibility testing by Alamar Blue, the method used here. 
One study suggests a critical MICKAN of 2.5 µg/mL for 
Alamar Blue testing. Since our inhibitors are able to return 
KAN-resistant isolates to an MICKAN below the critical 
35 and 12. Conventionally, Pd/C is a hydrogenation catalyst. In 
the absence of hydrogen gas, Pd/C is known to catalyze an 
oxidative aromatization instead of hydrogenation. More 
details about this heteroaromatic aromatization were sum-
marized in an excellent review. 19 Compounds 11 and 12 
Cpd# R1 R2 
la H H 
lb H o-F 
le H m-F 
ld H m-
Cl 
le H m-
Br 
w H m-
OH 
lg H m-
OMe 
lh H p-F 
li H p-Cl 
lj H p-Br 
40 were further reacted with the different substituted 2-bromo-
acetophenones to furnish the desired fully aromatized ana-
logues la*-k* and 2a*-k*. These compounds were evalu-
ated for Eis inhibition using the clinically relevant KAN as 
the AG substrate (IC50 values in Table 2). 
TABLE 2 
Inhibition of Eis-catalyzed KAN acetylation (IC50 values) by tbe pyrrolo[l,5-a]pyrazine 
derivatives as well as effect oftbese molecules on KAN MIC values for Mtb H37Rv and KAN-
resistant Mtb K204. 
H37Rv K204 H37Rv K204 
ICso MICKAN MICKAN ICso MICKAN MICKAN 
Aromatic (µM)" (µg/mLl (µg/mL)" Cpd# R1 R2 Aromatic (µM)" (µg/mLl (µg/mL)" 
no 0.9 ± 0.2 d d 2a p-F H no 0.47 ± 0.05 d d 
no 0.7 ± 0.2 _d _d 2be p-F o-F no 1.4 ± 0.4 _d _d 
no 0.05 ± 0.01 ,;1.25 10, 10 2c p-F m-F no 0.7 ± 0.2 d d 
no 0.5 ± 0.1 ,;1.25 10, 10 2d p-F m- no 0.15 ± 0.04 ,;1.25 >10, >10 
Cl 
no 0.44 ± 0.16 ,;1.25 10, 10 2e p-F m- no 0.07 ± 0.02 ,;1.25 >10, >10 
Br 
no 4.2 ± 1.7 d d 2f" p-F m- no 8.7 ± 1.6 d d 
OH 
no 0.15 ± 0.04 ,;1.25 10, 10 2ge p-F m- no 1.3 ± 0.4 _d _d 
OMe 
no 0.039 ± 0.007 ,;1.25 10, 10 2h p-F p-F no 0.23 ± 0.02 ,;1.25 10, 5 
no 0.31 ± 0.09 ,;1.25 5, 5 2i p-F p-Cl no 0.5 ± 0.1 d d 
no 0.76 ± 0.17 _d _d 2j" p-F p-Br no 1.6 ± 0.5 _d _d 
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TABLE 2-continued 
Inhibition of Eis-catalyzed KAN acetylation (IC50 values) by the pyrrolo[l,5-a]pyrazine 
derivatives as well as effect of these molecules on KAN MIC values for Mtb H37Rv and KAN-
resistant Mtb K204. 
H37Rv K204 H37Rv K204 
ICso MICKAN MICKAN ICso MICKAN MICKAN 
Cpd# R1 R2 Aromatic (µM)" (µg/mL/ (µg/mL)" Cpd# R1 R2 Aromatic (µM)" (µg/mL/ (µg/mL)" 
lk H p- no 0.64 ± 0.18 d d 2k p-F p- no 0.47 ± 0.08 d d 
Me Me 
la* H H yes 0.064 ± 0.008 ,;1.25 5, 5 2a* p-F H yes 0.35 ± 0.07 ,;1.25 5, 5 
lb* H o-F yes 0.21 ± 0.05 ,;1.25 5, 5 2b* p-F o-F yes 0.29 ± 0.07 ,;1.25 5, 2.5 
le* H m-F yes 0.06 ± 0.01 ,;1.25 5, 5 2c* p-F m-F yes 0.22 ± 0.05 ,;1.25 2.5, 2.5 
ld* H m- yes 0.025 ± 0.006 ,;1.25 5, 5 2d* p-F m- yes 0.06 ± 0.02 ,;1.25 5, 5 
Cl Cl 
le* H m- yes 0.34 ± 0.10 ,;1.25 2.5, 2.5 2e* p-F m- yes 0.06 ± 0.02 ,;1.25 5, 5 
Br Br 
lf* H m- yes 1.8 ± 0.5 ,;1.25 10, 5 2f*e p-F m- yes 8.4 ± 2.8 ,;1.25 10, 10 
OH OH 
lg* H m- yes 0.21 ± 0.07 ,;1.25 5, 5 2g* p-F m- yes 0.53 ± 0.11 ,;1.25 5, 2.5 
OMe OMe 
lh* H p-F yes 0.029 ± 0.007 ,;1.25 5, 5 2h* p-F p-F yes 0.13 ± 0.04 ,;1.25 1.25, 1.25 
li* H p-Cl yes 0.56 ± 0.20 ,;1.25 1.25, 1.25 2i* p-F p-Cl yes 0.18 ± 0.06 ,;1.25 2.5, 5 
lj* H p-Br yes 0.27 ± 0.01 ,;1.25 2.5, 2.5 2j* p-F p-Br yes 0.50 ± 0.13 ,;1.25 5, 2.5 
lk* H p- yes 0.19 ± 0.02 ,;1.25 2.5, 5 2k* p-F p- yes 0.08 ± 0.03 ,;1.25 2.5, 5 
Me Me 
3a m,p- H no 0.15 ± 0.05 ,;1.25 10, 10 
di-F 
3d m,p- m- no 0.043 ± 0.006 ,;1.25 >10, >10 
di-F Cl 
3h m,p- p-F no 0.11 ± 0.03 ,;1.25 10, 10 
di-F 
Control without an Eis 1.25 10 3k m,p- p- no 0.11 ± 0.03 ,;1.25 10, 10 
inhibitor: di-F Me 
aIC50 values against purified Eis_Mtb enzyme. 
b Anti-tubercular activity of KAN against Mtb H37Rv. 
c Anti-tubercular activity of KAN against Mtb K204. 
dThe inhibitor interacted with alamarBlue ® resulting in a color change, therefore, it was impossible to determine the MIC using this method. 
ein MIC assays, the compounds were tested at concentrations that were 100-fold higher than IC50. When the IC50 value was> 1 µM the compounds were tested at 100 µM. The compounds 
were not toxic to Mtb in the absence of KAN at these concentrations. 
We first tested whether the freshly synthesized parent 
compound la* was indeed a potent Eis inhibitor. Expect-
edly, the freshly synthesized compound la* was found to 
display potent inhibition of Eis (IC50=0.064±0.008 µM), 
which was -6-fold better than the IC50 value of the com-
mercially available compound la* (IC50=0.36±0.03 µM) 
from our previous HTS (Note: freshly synthesized powder 
are often more active than HTS library compounds, which 
may degrade upon storage).18 The hit scaffold la* contains 
a pyrrolo[l,5-a]pyrazine core, a phenyl ring adjacent to the 
pyrrolo[l,5-a]pyrazine core (containing R1), and an aceto-
phenone moiety ( containing R2 ). A comparison of the 
chemical structure of compound la* with those of the 
previously published isothiazole S,S-dioxide-based Eis 
inhibitors co-crystallized with Eis (FIG. 8)15 suggested that 
la* binds to Eis at the AG binding pocket20 similarly to the 
isothiazole S,S-dioxides. Examination of the Eis crystal 
structure bound to the AG tobramycin (TOB) (PDB: 4JD620) 
indicated that the positively-charged pyrrolo[l ,5-a ]pyrazine 
core is presumably essential for binding to the negatively-
charged AG binding pocket and thus, should not be modi-
fied. Based on our previous survey of the hits of this HTS, 18 
we also determined that the phenyl ring adjacent to the 
pyrrolo[l,5-a]pyrazine core (containing R1) is likely impor-
tant for Eis inhibition. In fact, replacing the phenyl ring of 
la* with an ethyl group resulted in a 25-fold reduction in the 
inhibitory activity (IC50=9.25±1.50 µM). 18 Also from the 
crystal structure of Eis in complex with the isothiazole 
S,S-dioxide-based Eis inhibitors, we have rationalized that 
this phenyl ring is important due to its snug fit in a 
hydrophobic binding pocket in the AG binding cavity. On 
the other hand, the it-electron rich acetophenone moiety 
(containing R2 ) and the fully aromatic pyrrolo[l,5-a]pyra-
zine core were predicted to be crucial for binding due to 
40 potential Jt-Jt interactions with aromatic residues within the 
Eis binding pocket. However, it remains unexplored whether 
and which substitutions at R1 and R2 positions would be 
beneficial. We hypothesized that: (i) tailor fitting the Eis 
binding pocket by introducing subtle modifications at R1 and 
45 R2 would lead to the discovery of novel optimized inhibitors 
from our hit scaffold la*, and (ii) disruption of the aroma-
ticity of the pyrrolo[l,5-a]pyrazine core would be detrimen-
tal to the binding affinity of the molecule to the Eis binding 
pocket. In our biochemical analysis, we will first examine 
50 the aromatic compounds and then explore their non-aro-
matic counterparts. Both the aromatic and non-aromatic 
molecules are divided into two series. In series 1, R1 was 
kept constant (R1 =H), and various substituted acetophe-
nones were installed onto the pyrrolo[l,5-a]pyrazine core 
55 (changing R2 ). Similarly, in series 2, R1 was kept constant 
(R1 =p-F), and the same various substituted acetophenones 
were installed onto the pyrrolo[l,5-a]pyrazine core (chang-
ing R2). For the non-aromatic compounds, four additional 
members were added to a third series (series 3) where R1 
60 was m,p-di-F. 
We began our analysis of the aromatic compounds by 
investigating series 1. To probe the ortho position of the 
acetophenone moiety, compound lb* (R1=H, R2 =o-F) was 
generated and found to display a -3-fold reduction in Eis 
65 inhibitory activity (IC50=0.21±0.05 µM) when compared to 
the freshly synthesized parent la* (Note: from here on, 
when comparing to la*, we refer to the freshly synthesized 
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la*), indicating that ortho substitution was not beneficial. 
We then explored substitutions at the meta position with 
compounds le*-lg*. The meta-substituted compound le* 
(R1=H, R2 =m-F) was found to have comparable Eis inhibi-
tory activity (IC50=0.06±0.01 µM) to the parent compound 5 
la*. We systematically increased the size of the halogen 
substituents in compounds ld* (R1=H, R2=m-Cl) and le* 
(R1=H, R2=m-Br). 
Interestingly, compound ld* displayed an IC50 value of 
0.025±0.006 µM, which was -3-fold smaller than that of the 10 
parent compound la*. On the other hand, compound le* 
(IC50=0.34±0.10 µM) was not as potent as compound ld*, 
suggesting that the Br substituent was possibly too sterically 
hindered and thus, not well tolerated in the Eis binding 
pocket. Compound lf* (R1=H, R2 =m-OH) (IC50=1.8±0.5 15 
µM) was less potent than the parent compound, which 
suggested that having a highly polar substituent could be 
disfavored. Alternatively, replacing the hydroxyl group by a 
methoxy (compound lg* (R1=H, R2 =m-OMe)) yielded a 
molecule with improved Eis inhibition (IC50=0.21±0.07 20 
µM) when compared to lf*. Overall, we found that the Cl 
was the best substituent at the meta position. We pondered 
whether this trend would translate to the para position, 
which prompted us to evaluate compounds lh* (R1 =H, 
R2 =p-F), li* (R1=H, R2=p-Cl), and lj* (R1=H, R2 =p-Br). 25 
Intriguingly, the smaller F substituent was optimal at the 
para position with an IC50 value of0.029±0.007 µM contrary 
to what we observed at the meta position. 
Intriguingly, inhibitor lh* displayed an IC50 of 
0.029±0.007 µM, which, similarly to the IC50 values for 30 
several other inhibitors was smaller than the half of the 
56 
ring. Additionally, the m-hydroxy and m-methoxy substitu-
tions, as in the cases of 2f* (R1 =p-F, R2 =m-OH) and 2g* 
(R1=p-F, R2=m-OMe) either completely abolished Eis 
inhibitory activity or resulted in moderate inhibition of the 
enzyme (IC50=8.4±2.8 and 0.53±0.11 µM, respectively). 
This was consistent with the observations made with com-
pounds lf* (R1=H, R2 =m-OH) and lg* (R1=H, R2=m-
OMe). For the para-substituted analogues (2h* (R1=p-F, 
R2=p-F), 2i* (R1=p-F, R2=p-Cl) and 2j* (R1=p-F, R2 =p-
Br)), similarly to what was observed with series 1, the larger 
halogen substituents were generally less favorable with 
activities varying in the range of 0.13-0.50 µM. We also 
evaluated the para-methylated analogue 2k* (R1 =p-F, 
R2=Me) and found that 2k* displayed excellent activity with 
an IC50 value of0.08±0.03 µM, which was 2-fold better than 
that of lk* (IC50=0.19±0.02 µM). 
Having established the general SAR trends for the aro-
matic analogues, we next aimed to determine whether their 
non-aromatic counterparts (la-k and 2a-k) would exhibit 
decreased activity due to potential disruption of the itDit 
interactions with Eis aromatic amino acid residues. Indeed, 
we found that most of the non-aromatic analogues generally 
displayed less potent Eis inhibition than their aromatic 
counterparts did. In four out of 22 cases, the aromatic and 
non-aromatic compounds display nearly equipotent inhibi-
tion of Eis. In the case of compounds le and le* (R1 =H, 
R2=m-F), the IC50 values were virtually the same 
(IC50=0.05±0.01 and 0.06±0.01 µM, respectively). Addi-
tionally, compounds 2e and 2e* (R1=p-F, R2 =m-Br) were 
also practically equipotent in terms of Eis inhibitory activi-
ties (IC50=0.07±0.02 and 0.06±0.02 µM, respectively). 
Compounds lg and lg* (R1=H, R2 =m-OMe) 
(IC50=0.15±0.04 and 0.21±0.07 µM, respectively) were also 
similar. For the pair li and li* (R1=H, R2 =p-Cl) 
enzyme concentration used in our assay (0.25/2=0.125 µM). 
This effect has at least three potential explanations: (1) If 
inhibition of one monomer per Eis hexamer by one inhibitor 
molecule leads to the loss of activity of the entire hexamer, 
then the IC50 can, in principle, be as low as 0.125/6=0.02 
µM; (2) If only a fraction of Eis protein is active in 
acetylating KAN and binding inhibitors (e.g., due to protein 
aggregation), then the concentration of active Eis in the 
assay is an overestimate of the concentration of active 
enzyme; and (3) If inhibitor binding to Eis causes Eis 
aggregation and inactivates multiple hexamers, then IC50 is 
also a fraction of the half of the enzyme concentration in the 
assay. Mechanism #3 is unlikely, because we do not observe 
global conformational changes in Eis upon inhibitor binding 
in crystal structures. Distinguishing among these mecha-
nisms of these highly potent analogues is a goal of ongoing 
work in the group. 
35 (IC50=0.31±0.09 and 0.56±0.20 µM, respectively), the non-
aromatic counterpart li was marginally better. Regardless of 
whether the analogue in series 2 was aromatic or non-
aromatic, it was conclusive that at the meta position of the 
acetophenone moiety, bigger halogen substituents such as Cl 
Subsequently, we investigated the effect of R1 substitu-
tions on the phenyl ring adjacent to the pyrrolo[l,5-a] 
pyrazine core. As the p-F substitution was one of the best in 
terms of activity when we varied R2 in series 1, we first 
decided to install the p-F substituent at the R1 position and 
generated series 2 analogues. Analogue 2a* (R1=p-F, R2 =H) 
displayed weaker Eis inhibition (IC50=0.35±0.07 µM) than 
did la*. Similarly to 1 b* (R1 =H, R2 =o-F), the ortho-sub-
stituted analogue 2b* (R1=p-F, R2=o-F) was also not opti-
mal. When we increased the size of the R2 substituents at the 
meta position, we observed that the larger halogens led to 
more potent Eis inhibition (Br=Cl>F) and yielded com-
pounds with IC50 values varying from 0.06 to 0.22 µM. 
Unlike compound le* (R1=H, R2=m-Br; IC50=0.34±0.10 
µM), them-Br substituted analogue 2e* (R1=p-F, R2 =m-Br; 
IC50=0.06±0.02 µM) was much more potent, which pointed 
to the possibility that changing R1 from H to p-F could lead 
to a slight variation in the binding orientation of the mol-
ecule, especially near the meta position of the acetophenone 
40 and Br were generally better suited, and at the para position 
of the acetophenone, the smaller F substituent was the best. 
Once our pyrrolo[l,5-a]pyrazine derivatives were opti-
mized for inhibition of the purified Eis enzyme in vitro, we 
set to confirm whether these compounds could display Eis 
45 inhibitory activity in the Mtb culture, by measuring the 
effect of the compounds on KAN MIC (MICKAN). Com-
pounds were tested in combination with KAN against the 
KAN-sensitive H37Rv Mtb strain as a control and against 
the KAN-resistant Mtb K204, which is H37Rv Mtb bearing 
50 a clinically occurring point mutation in the eis promoter 
leading to overexpression of Eis.4 Mtb H37Rv has an 
MICKAN of 1.25 µg/mL, whereas KAN-resistant Mtb K204 
has an MICKAN of 2:10 µg/mL. Active compounds were 
expected to resensitize Mtb K204 to KAN. The compounds 
55 were generally tested at concentrations that were 100-fold 
higher than their respective IC50 values in the enzymatic 
assays, to correct for the variation in the potency of Eis 
inhibition. Weakly potent compounds (IC50> 1 µM) were 
tested at 100 µMin the MIC assays. Mtb is notorious for its 
60 highly lipophilic and complex cell wall, which provides 
intrinsic resistance to many antibacterial compounds and 
presents an immense challenge for anti-tubercular drug 
discovery. Indeed, as shown in our previous Eis inhibitors 
studies, 15 some of the most potent in vitro compounds were 
65 not active in Mtb cultures. We also cannot exclude low 
solubility or aggregation of the compounds in the culture 
media as a reason for poor activity. Herein, we determined 
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the MIC values for KAN (MIC KAN) against Mtb K204 in the 
absence or presence of our Eis inhibitors and compared them 
to the MIC KAN of the drug-sensitive Mtb H37Rv strain. As 
anticipated, most compounds caused a reduction in the 
MICKAN for Mtb K204, overcoming KAN resistance. Poor 5 
Eis inhibitors such as compounds 1 fl' and 2:fl' with relatively 
high IC50 values were unable to resensitize Mtb K204 to the 
action of KAN. These observations, together with the lack of 
toxicity of these inhibitors when used without KAN for 
either Mtb strains, validate Eis inhibition as the principal 10 
mechanism of MIC KAN reduction by these compounds. Mtb 
H37Rv, for which MICKAN is virtually unaffected by the 
inhibitors, serves as an important negative control in this 
regard. Some of the good Eis inhibitors such as compounds 
le-le, lg, lh, 2d, 2e, 2h, 3a, 3d, 3h, and 3k did not 15 
resensitize Mtb K204 to the action of KAN despite their 
nanomolarIC50 values (MICKAN-"'10 µg/mL), indicating that 
these molecules may not go through the cell envelope. 
Compounds la*-le*, lg*, lh*, li, lj*, lk*, 2a*-2e*, 2g*, 
2i*-2k* partially restored activity of KAN (MICKAN=2.5-5 20 
µg/mL). Generally, the analogues in series 1 and 2 displayed 
better potency compared to the analogues in series 3 in Mtb 
culture. While the charged nature of these compounds may 
contribute adversely to the permeability of the compounds 
through the greasy mycobacterial cell envelope, their better 25 
solubility in aqueous solution when compared to other 
uncharged Eis inhibitors may offset this potential issue. 
Therefore, these compounds serve as valuable alternatives to 
uncharged Eis inhibitors of other scaffolds in further pre-
clinical development of Eis inhibitors as KAN adjuvants in 30 
TB therapy. Indeed, two compounds, li* and 2h*, are highly 
promising for future development, as they completely 
restore the potency of KAN, fully overcoming Eis upregu-
lation. 
58 
inhibitor 2k* is indeed bound in the AG binding site ( estab-
lished by our reported Eis-CoA-TOB crystal structure;20 
FIG. 8) and is stabilized in the bound state by numerous 
hydrophobic interactions with Eis. The pyrazine ring is 
stacked between the side chain of Glu401 of Eis and its 
C-terminal carboxyl group, with mutually orthogonal Jt-Jt 
interactions of the pyrazine ring with the indole ring of 
Trp36. This observation supports our initial hypothesis that 
the aromaticity of the pyrrolo[l,5-a]pyrazine core is crucial 
for activity and explains why aromatized compounds 
resulted in better activities during SAR analysis. Attached to 
the pyrrolo[l,5-a]pyrazine core, the acetophenone ring dis-
played parallel Jt-Jt interaction with Phe84 and showed that 
our prediction about the importance of the aromatic aceto-
phenone was correct. Additionally, the R2 -substituted aceto-
phenone fits in a hydrophobic environment ofLeu63, Trp36, 
andArg37. Hence, adding a polar hydroxyl group at R2 , such 
as in compounds lf, 1 fl', 2f, and 2:fl', destabilizes binding 
within the hydrophobic environment and results in weaker 
Eis inhibitory activity. Furthermore, the para position of the 
acetophenone ring is sterically restrained on all sides, being 
sandwiched between Phe84 and Trp36 and abutting Trp13 
and Met65, explaining why the larger groups in para posi-
tion, such as in compounds li/i*, lj/j*, 2i/i*, and 2j/j* 
resulted in decreased Eis inhibitory activities. This R2 bind-
ing pocket of Eis accommodates structurally similar substi-
tutions of our previously published inhibitors with different 
core scaffolds (FIG. 8). Otherwise, these previously reported 
inhibitors are bound in distinct orientations in the large AG 
binding cavity. As shown in FIG. 10 and in our SAR 
analysis, near the two meta positions of the acetophenone 
ring, there are spacious pockets allowing incorporation of 
larger substituents at the meta position without compromis-
ing activity. Lastly, the phenyl ring containing R1 is located 
Cytotoxicity to three different mammalian cell lines was 
tested for five representative potent Eis inhibitors (FIG. 7) in 
the absence and presence of KAN at the concentration of 50 
µg/mL (equivalent to 86 µM) greatly exceeding the MICKAN 
of Mtb. The negative control corresponded to no inhibitor 
treatment and was standardized as 100% cell survival. The 
positive control was a treatment with Triton 100-X®, where 
we observed most of the cells killed. The cytotoxicity data 
are presented in FIG. 7. We observed that at sub-IC50 
concentrations, our Eis inhibitors induced cell proliferation, 
thereby displaying > 100% cell survival. With the exception 
of compound le*, which at 50 µM exhibited significant 
cytotoxicity against one of the three cell lines, none of the 
compounds were cytotoxic against any of the three cell lines 
35 in a spacious binding pocket lined by the terminus of the 
phosphopantetheinyl tail of the CoA molecule, Asp26, the 
C-terminal carboxyl group, Ser83, and Phe24, explaining 
why a phenyl group is preferred over an ethyl group at the 
R1 position. In summary, the crystal structure of the 
up to 50 µM. Three compounds (li*, 2c*, 2h*) had no 
significant cytotoxicity up to 100 µM, without or with KAN. 
The lack of cytotoxicity indicates the absence of toxic 
off-target effects in the mammalian cells, strengthening the 
promise of these compounds as candidates for animal and 
clinical studies. Eis inhibitors appear to be less toxic when 
co-administering with KAN. Upon assessing the cytotoxic-
ity of KAN alone (FIG. 9) and Eis inhibitors alone (FIG. 7), 
one can observe that exposure to KAN or to Eis inhibitors 
alone at sub-IC50 concentrations promotes cell growth. This 
phenomenon of increased growth in the presence of small 
quantities ofxenobiotics has been previously observed.21 -25 
Due to this effect, co-treatment with KAN and Eis inhibitors 
may result in a faster cell growth than that for KAN alone. 
To rationalize our SAR study and understand the binding 
mode of our inhibitors to Eis, we determined a crystal 
structure of Eis in complex with CoA and inhibitor 2k* ( one 
of our best inhibitors; IC50=0.08±0.03 µM) at the resolution 
of 2.4 A (FIG. 10). The crystal structure demonstrates that 
40 EisC204A-CoA-inhibitor 2k* complex allowed us to 
explain our biological data and provides a basis for future 
additional structure-based development of Eis inhibitors. 
In conclusion, via a SAR study, we tailor-fitted Eis 
inhibitors possessing the pyrrolo[l,5-a]pyrazine core to its 
45 Eis binding pocket and identified multiple novel nanomolar 
potency inhibitors. We validated our hypothesis that the 
aromaticity of the pyrrolo[l,5-a]pyrazine core was impor-
tant for activity and that aromatic analogues were overall 
better inhibitors than their non-aromatic counterparts. 
50 For the aromatic analogues, our study indicated that the 
SAR strongly correlates with the size of the halogen sub-
stituent( s ). At the meta position of the acetophenone, bigger 
halogens such as Cl and Br were generally well tolerated. On 
the other hand, at the para position, substitutions of a smaller 
55 F atom and a methyl group produced analogues with sub-
stantially improved activities. The SAR analysis also 
revealed that the substitution of a polar functional group 
such as the hydroxyl group greatly perturbed the hydropho-
bic environment leading to decreased activity. These SAR 
60 observations were explained by the crystal structure analy-
sis, which will greatly facilitate future medicinal chemistry 
studies. Most significantly, by in vitro Mtb culture assays, 
we confirmed that our Eis inhibitors were capable of pen-
etrating the Mtb cell wall and cancelling the KAN-resistance 
65 ofMtb K204, which overexpresses Eis. As exemplified by a 
clinically used combination of a ~-lactamase inhibitor, cla-
vulanic acid, and penicillin, these Eis inhibitors may become 
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similarly significant as adjuvant molecules in a combination 
therapy with KAN to prevent emergence of and combat 
KAN resistance in MDR- and XDR-TB. 
60 
synthesized by a reaction of 2,3-dihydroxyquinoxaline with 
chlorosulfonic acid to generate sulfonyl chloride, which then 
reacted with different aniline derivatives to yield compounds 
29-47 (FIG. 12A). 
Example 3 5 Biochemical and Biological Testing of Sulfonamides 
29-47. 
This Example relates to the discovery and rational struc-
ture-based optimization via medicinal chemistry of promis-
ing sulfonamide Eis inhibitors that not only efficiently 
inhibit the purified enzyme, but also restore KAN suscep- 10 
tibility of KAN-resistant Mtb. We also present a crystal 
structure of Eis in complex with CoA and one potent 
To investigate the potential of these compounds as Eis 
inhibitors for use in combination with KAN, we evaluated 
their biochemical (IC50 values against purified Eis enzyme) 
and biological (effect on the MIC values of KAN in KAN-
sensitive Mtb H37Rv and in KAN-resistant Mtb K2042 ) 
properties in parallel studies (Table 3 and FIG. 15). 
TABLE 3 
IC50 values against purified Eis and KAN MIC values against Mtb H37Rv and Mtb K204 
in the absence and presence of the compounds at the specified concentrations. 
Concentration H37Rv MICKAN K204 MICKAN 
Compound # Ar X IC50 (~ M)" tested (~M/ (] g/mL)" (~g/mL/ 
1.25 10 
29 p-Br-Ph Me 0.08 ± 0.02 8 ,;1.25 2.5 
30 p-Br-Ph H 6.2 ± 1.3 100 ,;1.25 5 
31 Ph Me 5.8 ± 1.8 100 ,;1.25 5 
32 Ph H >200 100 ,;1.25 10 
33 p-iPr-Ph Me 0.25 ± 0.06 25 ,;1.25 2.5-5 
34 p-iPr-Ph H 10.6 ± 2.5 100 ,;1.25 5 
35 p-Cl-Ph Me 0.100 ± 0.045 10 ,;1.25 2.5 
36 o-OMe-Ph Me >200 100 ,;1.25 10 
37 m-F-Ph Me 3.0 ± 0.7 30 ,;1.25 5 
38 m-Br-Ph Me 0.056 ± 0.004 5.6 ,;1.25 2.5 
39 m-OMe-Ph Me 5.8 ± 1.2 100 ,;1.25 ,;1.25 
40 3,5-di-OMe-Ph Me 7.4 ± 3.3 100 ,;1.25 5-10 
41 m-Me-Ph Me 0.37 ± 0.09 37 ,;1.25 2.5-5 
42 m-Et-Ph Me 0.027 ± 0.012 2.7 ,;1.25 5-10 
43 m-iPr-Ph Me 0.23 ± 0.03 23 ,;1.25 2.5-5 
44 m-nBu-Ph Me 0.7 ± 0.3 70 ,;1.25 5-10 
45 m-tBu-Ph Me 27 ± 8 100 ,;1.25 5-10 
46 2-naphthyl Me 0.00024 ± 0.00010 100 ,;1.25 ,;1.25 
47 4-OMe-2-naphthyl Me 0.30 ± 0.08 100 ,;1.25 10 
aIC50 values and standard errors for inhibition of purified Eis enzyme, 
bCompounds were tested at concentrations that were either 100-fold higher than their IC50 or at 100 1 M if the IC50 value could not be 
achieved while keeping the DMSO concentration at sl % in test wells. At these concentrations, the compounds did not inhibit the growth 
ofMtb H37Rv or that ofMtb K204 when tested in the absence of KAN. 
c Anti-TB activity of KAN against Mtb H37Rv, 
d Anti-TB activity of KAN against Mtb K204. 
sulfonamide inhibitor, which reveals its mode of action, 
explains our SAR study and paves the way for further 
rational structure-based development of Eis inhibitors. 
Identification and Chemical Synthesis of Eis Inhibitors. 
To identify potential Eis inhibitor candidates, we used an 
established UV absorbance-based HTS assay12 to screen 
over 123,000 structurally diverse small molecules for their 
inhibition of KAN acetylation by the Eis_Mtb acetyltrans-
ferase in vitro. The screening of this molecular library 
against Eis_Mtb led to the identification of a sulfonamide 
scaffold (FIG. 12B). The HTS library contained 29 com-
pounds (1-29) with this core structure, and four (1, 3, 4, and 
29) were identified as hits (i.e., compounds displaying 
;;,;3-fold higher inhibition than the magnitude of the standard 
deviation). Compounds 2 and 5-28 were found not to inhibit 
Eis in the HTS. As compounds 16-28 were unable to inhibit 
Eis, we concluded that at least an aromatic ring attached to 
the nitrogen atom is important for inhibitory activity. While 
compounds 1, 3, and 4 displayed modest Eis inhibition, 
compound 29 potently inhibited Eis activity (IC50=0.5±0.1 
µM). Based on this encouraging result, we synthesized 
compound 29 along with 18 additional sulfonamide ana-
logues (30-47) containing a variety of substituents on the 
aniline ring to define a preliminary body of structure-activity 
relationship (SAR) of Eis inhibition. The compounds were 
Importantly, Mtb K204 is genetically identical to H37Rv, 
except for one clinically derived point mutation in the eis 
45 promoter that causes upregulation of Eis acetyltransferase 
resulting in the resistance of Mtb K204 to KAN.2 In this 
regard, H37Rv serves as an important Eis knockdown con-
trol for validating the mechanism of action of the Eis 
inhibitors in the bacterial cell. To correct out the effect of 
50 different potencies (IC50) of the Eis inhibitors as determined 
by the enzyme assay, in the MIC assays we used the 
inhibitors at concentrations that were 100-fold higher than 
their IC50 values, where achievable. The freshly synthesized 
compound 29 displayed robust inhibition of Eis in vitro 
55 (IC50=0.08±0.02 µM). When combined with KAN, sulfo-
namide 29, resulted in a four-fold reduced KAN MIC value 
(2.5 µg/mL) compared to KAN alone (10 µg/mL) for K204 
Mtb. This was a reduction almost to the MIC level of KAN 
in the KAN-susceptible Mtb H37Rv (1.25 µg/mL) parent 
60 strain. To gain insight into the importance of the substitution 
pattern on the aniline portion of the sulfonamide scaffold, we 
generated secondary (NHAr) and tertiary (N(Me)Ar) sulfo-
namides (29-47). Eis inhibition assays with the synthesized 
sulfonamides were carried out in combination with KAN. 
65 The non-methylated counterpart oflead compound 29, com-
pound 30, displayed lower Eis inhibitory activity 
(IC50=6.24±1.31 µM) and had a smaller effect than 29 did on 
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thy! group, but this led both to a loss of Eis inhibition and 
to a loss of the effect on MIC KAN (see next section). 
The Eis inhibitors lacked anti-Mtb activity in the absence 
of KAN in either tested strain (Table 3 ). Furthermore, most 
the KAN resistance in Mtb K204 (MICKAN=5 µg/mL). Two 
other non-methylated derivatives, 32 and 34, also resulted in 
lower Eis inhibitory activity (IC50>200 and 10.6±2.5 µM, 
respectively) and did not overcome KAN resistance in Mtb 
K204 (MICKAN=l0 and 5 µg/mL, respectively). These data, 
in conjunction with the fact that compounds 1 and 3-13 from 
the HTS did not display significant Eis inhibition, suggest 
that the N-methyl group is essential for efficient Eis inhibi-
tion and antitubercular activity. 
5 compounds sensitized the KAN-resistant Mtb K204 to 
KAN, as expected based on their 100-fold IC50 concentra-
tions used in these assays, with two compounds (39 and 46) 
completely cancelling the effect of the Eis upregulation in 
Mtb K204. The two compounds that were least potent in the 
Having established the importance of the N-methyl moi-
ety, we explored the effect of substitutions on the benzene 
ring of the aniline moiety. Removing all substituents on the 
benzene ring (compound 31) resulted in a 70-fold decrease 
in Eis inhibitory activity (IC50=5.8±1.8 µM) when compared 
10 enzymatic assay (32 and 36) and used in the MIC assay at 
concentrations below 1 00xIC50 were also inert in that assay. 
This general correlation of the potency in the enzymatic 
assays and their effect on MICKAN canceling that of Eis 
upregulation, taken together, validate inhibition of Eis by 
to that of lead 29 and did not overcome KAN resistance in 
Mtb K204, suggesting the importance of a substituted ani-
line for Eis inhibition and antitubercular activity. In general, 
para substitution (compounds 29 with a p-Br, 33 with a 
p-iPr, and 35 with a p-Cl) was found to be favorable and 
yielded compounds with IC50 values varying from 0.08-0.25 
µM, which overcame KAN resistance (MICKAN=2.5 µg/mL) 
15 these compounds as the mechanism of their sensitization of 
Mtb K204 to KAN. Synergistic growth inhibition in com-
bination with KAN by some effect other than Eis inhibition 
can be ruled out because the inhibitors do not change 
MIC KAN in H37Rv. The cell envelope ofMtb is a notoriously 
20 tough barrier, and some compounds penetrate the cell enve-
lope more readily than others in a manner that is not 
correlated with the IC50 values. This would explain the 
variability of MICKAN values in Table 3. 
in KAN-resistant Mtb. Interestingly, p-methoxy substitution 
resulted in a compound (14) that was found to be inactive 
during our HTS. To delineate if ortho or meta substitution 
would be more favorable than para substitution, we gener-
ated compounds 36 (with an o-OMe) and 39 (with a 
m-OMe). The o-methoxy substituted 36 was found to be 
completely inactive (IC50>200 µMand MICKAN=l0 µg/mL 
against Mtb K204), whereas the m-methoxy substituted 39 
was found to be a potent Eis inhibitor (IC50=5.8±1.2 µM) 
and was one of our two compounds to fully overcome KAN 
resistance in Mtb K204 (MICKANsl.25 µg/mL). It is impor-
tant to note that incorporating an additional m-methoxy 
group, as in compound 40, was detrimental for the overall 
activity of the molecule, which suggested that mono-substi-
tution is more promising than di-substitution. We also syn-
thesized the m-bromo derivative 38, which demonstrated a 
slightly improved Eis inhibitory activity (IC50=0.056±0.004 
µM) than did the corresponding para derivative 29, while 
also being able to overcome KAN resistance in Mtb K204 40 
(MIC=2.5 µg/mL). We also found that the m-iso-propyl 
derivative 43 and its para counterpart 35 displayed similar 
Eis inhibitory activity (IC50=0.23±0.03 and 0.25±0.06 µM, 
respectively) and resulted in identical KAN MIC values 
(2.5-5 µg/mL) against KAN-resistant Mtb. While the 45 
p-methyl derivative 15 was inactive in our HTS, its meta 
counterpart 41 displayed good Eis inhibition 
(IC50=0.37±0.09 µM) and some ability to overcome KAN 
resistance in Mtb K204 (MIC 2.5-5 µg/mL). These data 
suggest that mono-meta substitution is either equal or more 
advantageous then para, which is more beneficial than ortho. 
Based on these results, we generated additional m-alkylated 
sulfonamides (42, 44, and 45) and observed that longer or 
bulkier alkyl groups, although good for Eis inhibition, did 
not produce compounds capable of overcoming KAN resis-
tance in Mtb K204. Finally, with the hope of increasing any 
possible Jt-Jt interaction between the inhibitor and the AG-
binding site of the Mtb Eis, we generated compound 46, 
which showed a dramatic increase in Eis inhibitory activity 
(IC50=0.00024±0.00010 µM) and was found to completely 
overcome KAN resistance in Mtb K204 (MICKANsl.25 
µg/mL). Compound 46 is currently our most potent and 
promising Eis inhibitor that can be used in conjunction with 
KAN. Since compound 39 with the methoxy group in the 
meta position is one of our best compounds to fully over-
come KAN resistance in Mtb K204, we also synthesized 
compound 47 with a m-methoxy substitution on the naph-
To examine the selectivity of our two best inhibitors (39 
25 and 46) towards Eis, we next tested these two compounds 
against three other AAC enzymes: AAC(2')-Ic from 
Mtb, 19• 20 AAC(3)-IV from E. coli, 21 • 22 and AAC(6')-Ie/ 
APH(2")-Ia from Staphylococcus aureus. 23 • 24 Sulfonamides 
39 and 46 did not inhibit KAN acetylation by the AACs 
30 tested at concentrations as high as 200 µM with the excep-
tion of 39, which inhibited 15% of the AAC(2')-Ic activity 
when tested at 200 µM. These data demonstrate the high 
selectivity of our inhibitors towards Eis. 
Crystal Structure of EisC204A-CoA-Inhibitor 39 Com-
35 plex. 
50 
55 
60 
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In order to characterize the mechanism of our Eis inhibi-
tors, explain the SAR, and aid in future drug development, 
we determined the crystal structure of Eis in complex with 
CoA and inhibitor 39 at the resolution of 2.1 A (FIG. 13 and 
Table 4). 
TABLE 4 
X-ray diffraction data collection and refinement statistics 
for the EisC204A-CoA-inhibitor 39 ternary complex structure 
(PDB ID 5IV0). 
Data collection 
Space group R32 
Number of monomers per asymmetric unit 
Unit cell dimensions 
a, b, c (A) 175.2, 175.2, 122.3 
a, 13, y (0 ) 90, 90, 120 
Resolution (A) 50.0-2.1 (2.14-2.10)" 
Ila 16 (2.1) 
Completeness (%) 95.8 (97.7) 
Redundancy 3.9 (3.8) 
Rnerge 0.08 (0.50) 
Number of unique reflections 37,907 
Structure refinement statistics 
Resolution (A) 40.0-2.1 
R(%) 19.4 
Rfree (%) 21.9 
Bond length deviation (rmsd) from ideal (A) 0.006 
Bond angle deviation (rmsd) from ideal (0 ) 1.35 
Ramachandran plot statisticsb 
% of residues in most allowed regions 93.8 
% of residues in additional allowed regions 6.2 
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substituents in compound 4 7 led to a loss of activity, as both 
substitutions cannot be sterically accommodated. 
The overall conformation of Eis in complex with the 
inhibitor is similar to the previously reported crystal struc-
X-ray diffraction data collection and refinement statistics 
for the EisC204A-CoA-inhibitor 39 ternary complex structure 
(PDB ID 5NO). 
% of residues in generously allowed 
regions 
% of residues in disallowed regions 
0.0 
0.0 (0 residues) 
"Numbers in parentheses indicate the values in the highest-resolution shell. 
bindicates Procheck statistics.29 
5 ture.5 A notable conformational difference is that a part of a 
loop (residues 28-30) and a helix (residues 31-37) are shifted 
towards the inhibitor relative to their conformation in the 
structure without the inhibitor by 1-1.5 A, apparently in an 
induced-fit fashion, to maximize steric contacts. The indole 
Although sulfonamide 46 was our best compound in 
biochemical and biological studies, it did not co-crystallize 
with Eis. The crystal structure demonstrates that inhibitor 39 
is bound in the part of the AG-binding pocket that is formed 
by the N-terminal domain of Eis. The inhibitor binding site 
partially overlaps with the binding site ofTOB, as observed 
10 ring ofTrp36 in this helix is rotated by -40°, maximizing the 
stacking with the aniline ring and other interactions, as 
explained above. These small, but significant conforma-
tional changes likely precluded us from obtaining a correct 
model of a bound inhibitor by prior extensive computational 
in our previously reported structure of Eis-CoA-TOB (FIG. 
14),7 indicating that the Eis inhibitors are competitive with 
AGs. The inhibitor is apparently stabilized in the bound state 
by numerous hydrophobic interactions (FIG. 13, panels B 
and C). The shape of the inhibitor binding pocket and the 
interacting hydrophobic residues are not conserved in other 
AAC enzymes, explaining the observed selectivity of the 
inhibitors. Specifically, the aniline moiety is stacked 
between the rings of Phe84 and Trp36, with the methoxy 
group located in the hydrophobic pocket lined by the non-
polar stem of the Arg37 side chain, Phe84, Trp13, and 
Leu63. This explains why removing the aniline ring resulted 
15 docking simulations. Inhibitor 39 occupies a similar space in 
the AG binding pocket as a previously reported inhibitor 
with the isothiazole S,S-dioxide heterocyclic core (labeled 
13g in reference17) (FIG. 14 FIG. 14), but the orientations of 
the two inhibitors and their interactions with the protein side 
20 chains are largely different. The only common feature is the 
nearly coplanar binding of the methoxy- and the chlorophe-
nyl rings of the two respective inhibitors, with both rings 
sandwiched by Phe84 and Trp36 of Eis (FIG. 14 FIG. 14, 
panel B). In summary, the crystal structure of the EisC204A-
25 CoA-inhibitor 39 complex allowed us to fully explain our 
biochemical and biological data and provides a solid foun-
dation for further rational structure-based development of 
Eis inhibitors. 
in a loss of activity for compounds 13, 16, 17, and 23-27. 30 
The quinoxaline moiety stacks against Phe24, a residue that 
also interacts with TOB (FIG. 14, panel B), as previously 
observed in a crystal structure of an Eis-TOB complex (FIG. 
14).7 The NH group of the quinoxaline ring on the side of the 35 
sulfonamide forms a hydrogen bond with the carboxyl group 
of Asp26 (N---0 distance of 2.7 A) and the oxygen of the 
sulfonamide forms a hydrogen bond with the main chain 
nitrogen oflle28 (O-N distance of3.0 A). Our SAR studies 
showed that compounds with an N-methyl group of the 40 
sulfonamide moiety displayed higher Eis inhibitory activity 
than those with an NH group, which can be rationalized by 
the optimal van der Waals interaction of the methyl with 
Trp36 (the distance between the methyl C atom and the 
closest C of the Trp36 side chain is 3.6 A). Eliminating the 45 
methyl group would abolish this interaction, putting a polar 
NH in a hydrophobic environment, likely destabilizing 
binding (6 vs 37, 30 vs 29, 32 vs 31, and 34 vs 33). 
Replacing the aniline ring with an N-aryl piperazine (com-
pounds 18-22) resulted in a loss of Eis inhibitory activity 50 
when compared to the aniline ring. As described above, this 
part of the molecule is snugly fit in a hydrophobic pocket, 
which is too small to accommodate these larger groups. The 
ortho position of the aniline ring is flanked by the C-terminal 
residue Phe402 and it abuts Phe84, explaining why an ortho 55 
substitution, as in compound 36, resulted in a loss of Eis 
inhibitory activity. A bulky group such as n-butyl (44) or 
t-butyl ( 45) in meta position of the aniline ring would clash 
withArg37 that is structurally fixed by Jt-Jt stacking with the 
inhibitor, explaining the poor inhibitory activity of these two 60 
compounds. A meta,meta-disubstitution (40) resulted in a 
dramatic decrease in activity as the second substituent would 
clash with the side chain of Met65. Electron-donating 
groups such as methoxy (39) or a naphthalene ring (46) 
increase the Jt-Jt interaction of the aniline ring with Phe84 65 
and Trp36, explaining their stronger interactions in the 
AG-binding pocket of Eis. However combining the two 
In conclusion, the biochemical, biological, and structural 
studies described in this manuscript provide a proof-of-
principle of the activity of Eis inhibitors as promising KAN 
adjuvants. The SAR combined with the co-crystal structure 
will guide future development of these compounds for their 
clinical use against MDR- and XDR-TB. 
Example 4 
This example relates to development of inhibitors of Eis, 
which can be co-administered with KAN in order to prevent 
inactivation by Eis in Mtb. Here, we report the identification 
as well as the biochemical and biological characterization of 
several potent inhibitors of Eis that were able to restore the 
antibacterial activity of KAN in a KAN-resistant strain, Mtb 
K204. To clarify in atomic details the mode of action of 
these compounds and their structure-activity-relationships, 
we also determined crystal structures of EisC204A in com-
plex with CoA and two of these inhibitors. 
High-throughput screening leads to the identification of a 
promising Eis inhibitor scaffold. In order to identify Mtb Eis 
inhibitors, we carried out a HTS of molecular libraries 
comprising 123,000 structurally diverse small molecules 
using a previously reported Eis acetylation assay in the 
miniaturized format (FIG. la).25 The initial HTS assay was 
performed using the aminoglycoside neomycin B (NEO) as 
a substrate, which was selected over KAN to maximize the 
signal to noise ratio under the HTS conditions. However, 
KAN was used in all post-HTS assays, since it is the 
clinically relevant aminoglycoside. The HTS yielded 617 
hits containing an isothiazole S,S-dioxide heterocyclic core 
that were re-tested (FIG. 17). Of these 617 molecules, 133 
showed reproducible inhibition of Eis enzymatic activity in 
the same single-point HTS assay. Thirty-six of these 133 
compounds were chosen for further testing in dose-response 
assays, based on the potency of their inhibition of Eis in the 
HTS assay and the structural diversity of their chemical 
substituents (R1 and R2 groups). In a previous study of Eis 
inhibitors evaluating fewer molecules, 25 we demonstrated 
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that active compounds contained (i) a group that may 
become positively charged, usually an amine, or (ii) an 
aromatic group. The presence of either of these groups was 
therefore also a criterion for selection of compounds for 
dose-response testing. Additionally, we included four ana-
logues that were not a part of the original library, but which 
contained the same structural core (FIG. 16b). This process 
yielded a group of forty molecules, for which we determined 
IC50 values against purified Eis. We also measured the effect 
of these compounds on KAN MIC for KAN-susceptible 
(H37Rv) and KAN-resistant (K204) Mtb strains (Table 5), 
as described in the two following sections. 
TABLE 5 
Eis inhibition IC50 values of tested compounds and tbe 
effect of tbe compounds on kanamycin A MIC values against 
H37Rv and K204 Mtb strains. 
H37Rv 
Concentration MICKAN K204 MICKAN 
Cpd IC50 (µM)" tested (µM/ (µg/mL)" (µg/mLl 
1.25 10 
3i 0.120 ± 0.035 12 0.625 1.25 
6b 0.152 ± 0.045 15.2 0.625 2.5 
7b 0.102 ± 0.034 10.2 0.625 2.5 
Sa 2.85 ± 0.26 184.5 0.625-1.25 5 
Se 0.200 ± 0.036 20 0.625 2.5-5 
llc 0.238 ± 0.089 23.8 0.625 1.25 
12e 0.183 ± 0.043 18.3 0.625 2.5 
13a 2.82 ± 0.21 282.3 0.625 2.5 
13e 0.331 ± 0.071 33.1 0.625 2.5 
13g 0.234 ± 0.060 23.4 0.625 2.5-5 
13i 0.054 ± 0.002 5.42 0.625 5 
14c 0.112 ± 0.008 11.2 0.625 5 
15e 0.535 ± 0.045 53.5 0.625-1.25 5 
15f 0.148 ± 0.016 14.8 0.625-1.25 10 
17i 0.232 ± 0.038 23.2 0.625-1.25 5 
33a 0.123 ± 0.023 13.2 0.625 5 
35e >200 20 0.625 5 
35g 2.49 ± 0.49 100 0.625 2.5 
35h 3.23 ± 0.99 100 0.625 2.5 
35i 0.985 ± 0.190 98.5 0.625 2.5 
36d 0.152 ± 0.031 15.3 0.625 2.5-5 
37b 0.657 ± 0.105 65.7 0.625 2.5-5 
37d >200 20 0.625-1.25 5-10 
46a 0.432 ± 0.057 43.2 0.625-1.25 10 
46b 0.092 ± 0.021 9.21 0.625-1.25 5 
46c 0.109 ± 0.022 10.9 0.625 2.5 
46h 0.135 ± 0.031 13.5 0.625 5 
52i 0.580 ± 0.096 58 0.625 2.5 
62i 0.386 ± 0.080 38.6 0.625 5 
81b 1.25 ± 0.22 124.8 0.625 2.5-5 
81g 1.42 ± 0.42 142.3 0.625 2.5 
87b >200 20 1.25 10 
89b >200 20 1.25 10 
112b >200 20 0.625 10 
112i 0.621 ± 0.229 62.1 0.625 5 
115i >200 20 0.625 10 
116i >200 20 1.25 10 
139b >200 20 0.625 10 
139e >200 20 1.25 10 
139i >200 20 1.25 10 
aTbe IC50 values in the Eis acetyltransferase assay. 
b At these concentrations, these compounds did not inhibit the growth ofH37Rv or that of 
K204 Mtb, when tested in the absence of KAN. 
"KAN MIC values for H37Rv Mtb in the absence (first line) and in the presence of each 
compound at the specified concentrations. 
dSame as c, but for K204 Mtb. 
Structure-Activity Relationship Studies. 
Various R1 and R2 side-chains in the identified isothiazole 
S,S-dioxide heterocyclic scaffold (FIG. 16b, FIG. 17), were 
explored to improve anti-Eis potency in vitro. Based on the 
617 initial HTS hit molecules, we first drew several unam-
biguous conclusions about the desirable structure of the R2 
side-chain. Most of the compounds for which R2 contained 
66 
an aromatic ring, a branched alkyl group, a cyclohexyl 
moiety, or a benzyl functionality did not efficiently inhibit 
Mtb Eis. Among the forty compounds that were pursued 
beyond the dose-response assay, compounds containing R2 
5 groups 8, 13, 15, 35, 46, and 81 inhibited Eis in vitro when 
combined with multiple R1 substituents, while other R2 
groups were shown to inhibit Eis in dose-response assays 
when in combination with only one of the possible R1 
substituents (6b, 7b, Ile, 12e, 14c, 17i, 33a, 36d, 37b, 52i, 
10 62i, and 112i). Overall, two large families ofR2 substituents 
emerged as potential potent inhibitors of Eis: (i) compounds 
with R2 containing two nitrogen atoms separated by three 
carbon atoms (structures 3, 6-8, 11-15, and 17), particularly 
compounds with large bulky groups or a cyclohexyl ring 
15 attached to the extended nitrogen atom were most often 
inhibitory; and (ii) compounds containing an R2 group with 
two nitrogen atoms separated by two carbon atoms also 
efficiently inhibited Eis (structures 33, 35-37, and 112). In 
20 
25 
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35 
40 
45 
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this series of molecules, only compounds with a nitrogen 
atom located in a cyclohexyl ring were inhibitory. 
We next explored the effect of the R1 substituents on Eis 
inhibition. Upon initial inspection of the 617 HTS hits, the 
identity of the R1 substituent appeared to have little effect on 
their Eis inhibitory activity. However, when analyzing these 
side chains statistically, patterns emerged. The p-fluorophe-
nyl group (b) had the highest percentage (34%) of com-
pounds inhibiting Eis in the initial HTS; this was followed 
closely by the p-methylphenyl group (e, 33%) and the 
m,p-dimethylphenyl group (i, 30%), suggesting that these 
three groups as R1 substitutions have a better chance of 
contributing positively to Eis inhibition. The next best R1 
substituent was the p-chlorophenyl group (c) with 27% of 
the compounds within this group displaying inhibition of 
Eis. The m-chlorophenyl group (g) and p-anisole group (d) 
were next with 19% and 18% of their compounds displaying 
Eis inhibition, respectively. Finally, with 13%, 12%, and 9% 
of compounds showing Eis inhibition were compounds 
containing the p-isopropylphenyl (f), the m-bromophenyl 
(h), and the phenyl (a) group as Ri, respectively. 
Having established general trends for the R1 and R2 
substituents, we next focused on the measured in vitro 
potency (IC50) of the forty selected compounds (Table 5). 
Several trends consistent with those established above 
emerged from these quantitative data. With the exception of 
compound 112i, mono-substituted R2 amine substituents 
comprised of a straight alkyl chain (139b, 139e, 139i), an 
aromatic ring (87b, 89b, 112b ), or an amide functionality 
(115i, 116i) did not inhibit purified Eis. Compounds with R2 
substituents containing a diamine separated by two carbon 
atoms with the second amine present in a cyclohexyl ring all 
displayed good to moderate Eis inhibition. However, no 
conclusion could be formed as to what type of cyclohexyl 
ring was best, an unsubstituted (33a), a morpholino (35e, g, 
h, and i), or a piperazinyl (36d or 37b) ring, as most IC50 
values were similar for these compounds. Compound 13i 
with a diamine separated by three carbons at the R2 position 
and the m,p-dimethylphenyl group at the R1 position was 
found to be the most potent Eis inhibitor (IC50=0.054±0.002 
µM). Interestingly, compound 46b with a cyclohexyl ring 
directly attached to the core scaffold followed by a second 
piperazine ring in the para-position was found to be the 
second best Eis inhibitor (IC50=0.092±0.021 µM). These 
results indicate that both a rotationally free alkyl chain (as in 
compound 13i) or cyclically restricted alkyl linkers could be 
useful in designing Mtb Eis inhibitors. 
To establish whether the inhibitors identified were specific 
to Eis over AACs from other families, compounds 46b and 
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46c were tested against AAC(6')-Ie/APH(2")-Ia from 
Staphylococcus aureus, 26' 27 AAC(3 )-IV from E. coli, 28 and 
AAC(2')-Ic from Mtb.29 '30 Under optimal reaction condi-
tions for each enzyme, no inhibition by either compound 
was observed with any of these AACs (Table 6). These data 5 
demonstrate that the compounds are exquisitely selective for 
Mtb Eis over other AACs. 
Crystal Structures of Eis-Inhibitor Complexes Reveal the 
Inhibition Mechanism. 
To elucidate the mechanism of Eis inhibition by the 
isothiazole S,S-dioxide heterocyclic core-containing com-
pounds, rationalize the observed SAR, and guide future 
rational inhibitor design, we determined 2.2 A-resolution 
crystal structures of Eis in complex with CoA and inhibitors 
13g and Ile (FIG. 18a,c), which displayed both potent 
inhibition of Eis acetylation in vitro and the KAN resistance TABLE 6 
Inhibition of different non-Eis AACs by compounds 
46b and 46c. 
Concentrationa 
Compound AAC (µM) % activityb 
46b AAC(2')-Ic 200 100 
46b AAC(3)-IV 200 100 
46b AAC(6')-lec 200 80 
46c AAC(2')-Ic 200 100 
46c AAC(3)-IV 200 100 
46c AAC(6')-Ie 200 75 
aMaximum inhibitor concentration tested. 
bThe activity of the enzyme at the maximum inhibitor concentration (200 µM) relative to 
that without inhibitor. 
cThe acetylation activity of AAC(6')-Ie/APH(2")-Ia enzyme. 
10 abolishing effect in the Mtb cultures. Both inhibitors and 
their chemical features were clearly distinguishable and 
modeled into strong F 0 -F c electron density (FIG. l8b,e). The 
only exception was the 1,2,3,4-tetrahydroisoquinoline group 
of l le, for which only partial electron density was observed 
15 (FIG. 18e), likely due to a somewhat dynamic behavior of 
this highly hydrophobic group in a partially polar environ-
ment, as allowed by the flexible diamine linkage. No other 
significant difference electron density that could be attrib-
uted to a bound inhibitor was observed elsewhere. Both 
20 inhibitors exhibited highsteric complementarity with the Eis 
surface. The binding site for both inhibitors overlapped with 
the aminoglycoside substrate-binding site, as was recently 
established by the structure ofMtb Eis in complex with CoA 
Eis Inhibitors Abolish Eis-Mediated Resistance of Mtb to 25 
KAN. 
and tobramycin (FIG. 18cj; FIG. 20 FIG. 20 FIG. 20). 10 In 
addition, the R2 groups of both inhibitors reached the C-ter-
minal carboxyl group of Eis, which was proposed to serve 
Having identified inhibitors of purified Mtb Eis enzyme, 
we next determined their activity in cellulo. Mycobacteria 
are notorious for their waxy cell wall that is difficult to 
penetrate for small molecules. Therefore, we anticipated that 
not all of the compounds that exhibited inhibition of purified 
Eis would be effective in cell cultures. We measured the 
effect of the forty selected compounds (at a concentration of 
100-fold higher than their IC50 values) on KAN MIC values 
against Mtb K204, a KAN-resistant strain bearing a clini-
cally observed eis promoter mutation known to upregulate 
Eis production (Table 5). In the KAN-susceptible H37Rv 
strain, the MIC value of KAN is 1.25 µg/mL, whereas in the 
KAN-resistant K204 strain, the MIC value of KAN is 10 
µg/mL. As expected, compounds that did not inhibit purified 
Mtb Eis (35e, 37d, 87b, 89b, 112b, 115i, 116i, and 139b, e, 
and i) did not overcome resistance to KAN in Mtb K204. 28 
of the remaining 30 Eis inhibitors resulted in at least a 2-fold 
reduction in KAN MIC against Mtb K204, with two of these 
compounds, 3i and Ile, lowering KAN MIC 8-fold, down to 
the level of the KAN-susceptible H37Rv strain. Notably, 
these compounds did not have any effect on growth of either 
mycobacterial strain in the absence of KAN. Therefore, 
these compounds act synergistically with KAN against 
KAN-resistant Mtb. The compounds that reduced the MIC 
value of the KAN-resistant Mtb strain 4-fold had IC50 values 
that ranged from 0.102±0.034 to 3.23±0.99 µM. Generally, 
as the general base in the acetyl transfer reaction. Therefore, 
these crystal structures indicate that the inhibitors block 
access of aminoglycosides to the active site of the enzyme. 
30 Explaining the critical role of the isothiazole S,S-dioxide 
heterocyclic core, this group is bound in the same location 
and orientation in both Eis-inhibitor structures (FIG. 18). 
Remarkably, despite the nearly identical positions of this 
group, there are differences in how this group interacts with 
35 the protein for the two inhibitors. These differences are due 
to significant conformational changes in the region spanning 
residues 26-31 of Eis (FIG. l8b,e), which uniquely adapts to 
bind the two structurally different R2 groups. For inhibitor 
13g (FIG. l8a,b,c), one of the sulfonyl oxygens forms a 
40 direct hydrogen bond with the main chain amide nitrogen of 
Phe84 and the ring nitrogen forms a water-mediated hydro-
gen bond with the main chain amide nitrogen oflle28. In this 
case, the Eis conformation resembles that observed in a 
previously reported crystal structure with the aminoglyco-
45 side-binding pocket unoccupied4 . Inhibitor Ile does not 
make any water-mediated contacts due to a small positional 
shift of the inhibitor and a conformational change of Eis. 
Instead, the two sulfonyl oxygens are at a distance of -4 A, 
consistent with the stabilizing van der Waals and electro-
50 static interactions. The isothiazole ring is sterically sand-
wiched between the side chains of Ile28 and Ser83 in one 
in vitro (Eis inhibition) and in cellulo (KAN-sensitization) 
activities were correlated among the compounds tested in 55 
both assays. This correlation, together with the lack of 
inhibition of cell growth in the absence of KAN, serve as a 
strong evidence for inhibition of KAN acetylation by Eis as 
the principal mechanism of action in the mycobacterial cell. 
Not unexpectedly, among very potent inhibitors of the 60 
enzymatic activity of Eis in vitro, a small fraction of the 
compounds had little or no effect at sensitizing the resistant 
Mtb strain K204 to KAN. The lack of activity in the cells 
was likely due to the inability of these compounds to go 
through the cell envelope or due to their aggregation in the 65 
cell culture media at the concentrations that were much 
direction and between the side chains of Phe24 and Trp36 in 
the orthogonal direction. The R1 groups of the two com-
pounds are almost coplanar and fit neatly into a nearly fully 
nonpolar environment of side chains Leu63, Trp13, and 
Ala33, the aliphatic stem of Arg37, Met65, and Phe84, 
explaining the nonpolar phenyl ring with small substitutions 
as effective R1 groups (FIG. 16). Such environment, devoid 
of hydrogen bond donors or acceptors is appropriate for 
accommodating halogen substituents, as is the case with 11 c 
and 13g. The halogens can be accommodated in the para 
and/or one, but not both meta positions. Substitutions at both 
meta positions would not be accommodated, as reflected in 
the list of potent inhibitors (FIG. 16), since one of them 
would clash sterically with the side chain of Met65. In 
contrast with R1 , the conformations of the R2 groups of the 
two inhibitors are drastically different with one exception-higher than those used in the enzymatic assay. 
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the positively charged ring nitrogen of R2 occupies nearly 
the same location where it forms a salt bridge with the 
carboxyl group of Glu401 in both structures. Besides this 
interaction, R2 group of compound 13g makes steric and 
weak electrostatic interactions with His119, Ser121, 5 
Glu401, and the C-terminal carboxyl group (weakly elec-
trostatically interacting with the stem N) on one side and 
making water-mediated steric interactions with region 26-31 
on the other side. In contrast, for the R2 of the compound 
l lc: while the interactions with one face of this group are 10 
made with the same amino acid residues, the other face 
interacts directly through hydrophobic and steric interac-
tions with the region 26-31, which is in a different confor-
mation. Most prominently, the side chain of Asp26 is flipped 
to interact with the stem, and Phe24 orthogonally stacks 15 
against the double ring. Because the R1 group abuts the 
hydrophobic wall, whereas R2 group points towards the 
more extended end of the substrate binding channel, there is 
more variability in both the identity and the size of R2 
substituents, as exhibited in the list of effective R2 groups 20 
(FIG. 17). 
TABLE 7 
70 
pool of compounds tested, we found agents that we validated 
as potent inhibitors of Eis both in the test tube and in the 
relevant Mtb cultures. Using a -5-fold larger and more 
structurally diverse compound library than that used in our 
initial effort25 yielded compounds that were 10-fold and 
more potent than those reported in that previous study. 
Potencies in mid-nM range appear to be achieved through 
binding of the compounds via steric complementarity, 
hydrophobic and hydrogen bonding interactions. While one 
substituent group (R1 ) is relatively unchangeable in terms of 
its size and physico-chemical properties, the other group 
(R2 ) can greatly vary. The crystal structures of Eis-inhibitor 
complexes demonstrate that binding to variable structures is 
accompanied by conformational plasticity of the aminogly-
coside-binding site of Eis, which adapts to different R2 
groups, while the protein-R1 interactions are rigid body-like. 
Binding of the two inhibitors of Eis investigated structurally 
differs not only in protein conformation, but also in the 
presence or absence of water-mediated contacts. Interest-
ingly, the exquisite selectivity and potency of Gleevec 
towards its target Ab! kinase have been recently elegantly 
X-ray diffraction data collection and refinement statistics for the EisC204A-CoA-
inhibitor 11c and EisC204A-CoA-inhibitor 13g ternary complex structures. 
Data collection 
Space group 
Number of monomers per asymmetric unit 
Unit cell dimensions 
11c 13g 
a, b, c (A) 
□,□,□(") 
Resolution (A) 
II□ 
175.2, 175.2, 122.3 
90, 90, 120 
175.6, 175.6, 122.2 
90, 90, 120 
50.0-2.2 (2.24-2.20)" 
21 (2.9) 
50.0-2.2 (2.24-2.20)" 
24 (4.0) 
Completeness (%) 
Redundancy 
Rmerge 
99.9 (100) 99.8 (99.4) 
9.5 (9.4) 7.3 (7.3) 
Number of unique reflections 
Structure refinement statistics 
0.11 (0.62) 
34,661 
0.10 (0.56) 
34,541 
Resolution (A) 40.0-2.2 40.0-2.2 
R(%) 19.4 20.0 
Rfree (%) 21.5 23.8 
Bond length deviation (rmsd) from ideal (A) 0.006 0.007 
Bond angle deviation (rmsd) from ideal (0 ) 1.34 1.46 
Ramachandran plot statisticsb 
% of residues in most allowed regions 94.1 93.2 
% of residues in additional allowed 5.9 
regions 
% of residues in generously allowed 0.0 
regions 
% of residues in disallowed regions 0.0 (0 residues) 
"Numbers in parentheses indicate the values in the highest-resolution shell. 
bindicates Procheck statistics.8 
While it has been met with initial skepticism, target-based 
rational drug design is now gaining momentum and is 
widely used in industrial and academic drug discovery 
pipelines, due to advances in HTS technology, robust assay 
development practices and availability of large and diverse 
chemical libraries. Prominent examples of successful ratio-
nal drug design are HIV protease inhibitors ritonavir and the 
anticancer drug Gleevec. Here, we report the discovery and 
initial preclinical development of novel first-in-class isothi-
azole S,S-dioxide heterocyclic inhibitors of a unique acetyl-
transferase Eis from Mtb as an agent that overcomes one 
mechanism of resistance to KAN in Mtb. Among the diverse 
6.8 
0.0 
0.0 (0 residues) 
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shown to be a consequence of an induced-fit mechanism, 
where Ab! undergoes unique conformational changes that 
stabilize Gleevec in the binding site of this kinase and result 
in a nM aflinity. 31 Our Eis inhibitors also appear to be 
60 selective in that they do not inhibit other AAC enzymes. This 
selectivity must be due to the structurally different substrate 
binding pocket of Eis from that of regiospecific AAC 
enzymes. Indeed, we demonstrated previously that even 
though Mtb Eis shares main catalytic residues with Eis 
65 homologues from different bacteria and even AAC(2')-Ic, 
their substrate binding pocket topographies and the surface 
charges differ dramatically. 12 For example, the C-terminal 
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domain of Eis contributing to the shape of the substrate 
binding pocket (and containing inhibitor interacting residue 
Glu401 and the C-terminal carboxyl group) is absent in the 
single-domain AAC(2')-Ic and other AAC enzymes.4 
Aminoglycosides are among the antibiotics of last resort 5 
for MDR and XDR-TB patients, and resistance to them 
strongly decreases the chances of a favorable treatment 
outcome. The strategy of using KAN in combination with an 
Eis inhibitor is meant not only to overcome KAN resistance 
due to Eis upregulation, but also to curb emergence of new 
10 
resistant strains by mutagenesis of the eis promoter, as such 
mutation would not have survival benefit in the face of 
combination therapy. This study not only validates AAC' s as 
drug targets, but has set an important precedent for HTS-
driven discovery for AACs that cause resistance in clinically 
useful non-TB pathogens, such as AAC(3) and AAC(6') in 15 
Klebsiella pneumoniae. 32-34 As with TB, such inhibitory 
agents could play an important role in both overcoming 
existing resistance and curbing the acquisition of resistance. 
We identified potent inhibitors of Eis enzymatic activity 
with resulting sensitization of KAN-resistant Mtb cells, in 20 
which the resistance to KAN is caused by Eis upregulation. 
The inhibitors bind in the aminoglycoside binding pocket 
blocking the access of aminoglycosides to the active site of 
the enzyme. The inhibitor binding is accompanied by con-
formational changes of the protein. These compounds have 25 
a great potential for further development as KAN adjuvants 
in Mtb. 
Example 5 
30 
This example relates to development of inhibitors of Eis. 
The following compounds were prepared: 
35 
40 
45 
50 
55 
60 
65 
72 
73 
-continued 
HSYNH, 
N--NH 
1/ 
0 
N 
J; 
US 10,253,035 B2 
74 
-continued 
75 
-continued 
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and 
Inhibition kinetics. IC50 values were determined on a 
multimode SpectraMax MS plate reader using 96-well plates 
(Thermo Fisher Scientific) by using the UV-Vis assay as 
20 above taking measurements every 30 s for 20 min. Com-
pounds were dissolved in Tris (50 mM, pH 8.0 adjusted at 
rt containing 10% v/v DMSO) (100 l&L) and a 5-fold 
dilution was performed. To the solution of inhibitors, a 
mixture (50 l&L) ofEis (1 mM), NEO or KAN ( 400 l&M), 
25 and Tris (50 mM, pH 8.0 adjusted at rt) was added and 
incubated for 10 min, to allow for competitive binding. 
Reactions were initiated by addition of a mixture (50 l&L) 
containing AcCoA (2 mM), DTNB (2 mM), and Tris-HCl 
(50 mM, pH 8.0 adjusted at rt). Initial rates (first 2-5 min of 
30 reaction) were calculated, normalized and zeroed to appro-
priate controls. All assays were performed at least in tripli-
cate. Data was fit to a Hill-plot fit using KaleidaGraph 4.1 
software and IC50 values were calculated, and results are set 
forth in FIG. 21. 
35 In order to assess the potential cytotoxicity of our inhibi-
tors to mammalian cells, we selected our best Eis inhibitors 
and tested their cytotoxicity alone or in the presence of KAN 
againstA549, HEK-293, and J774A.1 cells. The percent cell 
survival was summarized and presented in FIG. 22. 
40 500 "'M (FIG. SX), we decided to perform the above 
toxicity experiments with Eis inhibitors in the presence of 
50 "'g/mL KAN ( equivalent of 86 "'(M), which is 10-40x 
MIC of KAN against Mtb H37Rv in order to better assess 
the combined toxicity of Eis inhibitors and KAN (FIG. X). 
45 Experiments were done in quadruplicate. 
All publications, patents, and patent applications men-
tioned in this specification are herein incorporated by ref-
erence to the same extent as if each individual publication, 
patent, or patent application was specifically and individu-
50 ally indicated to be incorporated by reference, including the 
references set forth in the following list: 
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